
























The Dissertation Committee for Rafaella Sale 
certifies that this is the approved version of the following dissertation: 
 
 
Evaluation of a Progress Monitoring and Feedback Intervention  










Evaluation of a Progress Monitoring and Feedback Intervention  














Presented to Faculty of Graduate School 
of the University of Texas at Austin 
in Partial Fulfillment  
of the Requirements  
for the Degree of  
 
Doctor of Philosophy 
 






Evaluation of a Progress Monitoring and Feedback Intervention  
in a Community Mental Health Center for Youth 
 
by 
Rafaella Sale, PhD 
The University of Texas at Austin, 2020 
SUPERVISOR: Sarah Kate Bearman 
 
 Clinicians often have difficulty accurately predicting whether their patients are progressing 
as planned while enrolled in therapy. Use of a measurement feedback system (MFS) has been 
shown within the adult literature to improve mental health treatment outcomes, especially for those 
who are most likely to dropout from treatment. An MFS’s effects are theorized to work through 
clinician behavior (i.e., tailoring treatment) that is elicited in response to receiving patient 
feedback. The current study examined an MFS’s effects on treatment length and dropout rate after 
being implemented in one community mental health center for youth (n = 538; 57% male, 52% 
Latinx/Hispanic, M age = 9.80). Level of clinician implementation of the MFS was also examined, 
and higher levels were found to impact treatment outcomes. Limitations include systemic issues 
related to archival data, including use of a historical control. Clinical and theoretical implications 
of these findings are discussed, in addition to recommended next steps for researchers interested 
in dissemination and implementation of effective mental health treatment.
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Approximately 26-37% of children meet criteria for one or more psychological disorders 
by adulthood (American Psychiatric Association [APA], 2000; Costello, Mustillo, Erkanli, Keeler, 
& Angold, 2003; Costello, He, Sampson, Kessler, & Merikangas, 2014). Twenty-five percent of 
children meet criteria for two psychological disorders at any given time (Costello et al., 2003). 
Psychotherapeutic intervention is often recommended as the first line of treatment, yet up to 80% 
of individuals who enroll into mental health services through community providers do not 
significantly improve over an episode of care (Amble, Gude, Stubdal, Andersen, & Wampold, 
2015; Davidson et al., 2017). Approximately half of youth who present for mental health services 
do not improve and 15-24% worsen while in treatment (Cooper, Stewart, Sparks, & Bunting, 2013; 
Smith & Jensen-Doss, 2017; Warren, Nelson, Mondragon, Baldwin, & Burlingame, 2010). 
Clinical worsening, or deterioration, after enrolling into therapy is believed to be grossly 
underestimated, since individuals must complete measures on at least two separate occasions in 
order to be documented as “deteriorated” (Boswell, Kraus, Miller, & Lambert, 2015). In actuality, 
the majority of patients preemptively terminate from treatment (i.e., “dropout”) before their 
symptoms improve (McClintock, Perlman, McCarrick, Anderson, & Himawan, 2017), and never 
return to complete post-treatment assessment measures. 
Therapists typically underestimate their patients’ clinical worsening and overestimate their 
improvement. One study surveyed 129 mental health professionals in private practice to collect 
their estimates for the proportion of their patients who improve or deteriorate before leaving 
treatment (Walfish, McAlister, O’Donnell, & Lambert, 2012). Approximately 58% of respondents 
estimated that 80% or more of their patients improved, and 21% of respondents believed 90% or 
more of their patients improved before treatment ended. When asked to rate their therapeutic skills 
compared to other clinicians, 92% of the sample rated themselves above the 75th percentile 
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(Walfish et al., 2012). It is possible that this study returned responses from a subgroup of highly 
successful clinicians, though it is more likely that clinicians are poorly equipped to accurately 
predict patient trajectories throughout care. One study examined clinicians’ therapy progress notes 
in order to evaluate perceptions of deterioration (Hatfield, McCullough, Frantz, & Krieger, 2010). 
Specifically, researchers reviewed the progress notes of patients who had worsened from one 
session to the next by at least two times the number of points to count as “reliable change,” (i.e., 
patients who experienced a dramatic deterioration). Even though clinicians had access to their 
patients’ measurement data, less than one-third of their case notes included any information that 
referenced patients’ worsening of symptoms (Hatfield et al., 2010).   
Whereas clinical judgment for detecting clinical worsening may be faulty, actuarial 
methods may be better suited to predict patient trajectories. In another study, 48 clinicians were 
asked how many patients out of a sample of 550 would end treatment in a worsened state (Hannan 
et al., 2005). Responses were compared to results from an empirical algorithm that took into 
account symptom severity at intake and trajectory of response to predict how likely an individual 
was to drop out from treatment, based on a database of past patient trajectories. Out of the 550 
patients, 40 actually deteriorated across sessions before dropping out of treatment. Clinicians 
successfully predicted deterioration in one of these patients, while the algorithm accurately 
predicted 36 patients (86% of the deteriorated subsample) (Hannan et al., 2005). Furthermore, the 
algorithm was able to identify these patients by the 3rd session (Hannan et al., 2005). For youth, a 
similar actuarial method used to alert clinicians to risk of treatment failure accurately predicted the 
treatment trajectories for 71% of 2,715 cases, based on youth report alone (Cannon, Warren, 
Nelson, & Burlingame, 2010).  
 
 3 
Clinician subjective judgement has been found to be inconsistent and, at times, biased 
(Walfish et al., 2012; Tracey, Wampold, Lichtenberg, & Goodyear, 2014). For example, Treichler 
& Spaulding (2018) provided evidence that type of training and years of experience may impact 
how a clinician rated patient motivation, social skills, and participation in treatment. The same 
study also revealed gender bias in play, as males were perceived as being more engaged in 
treatment than females (Treichler & Spaulding, 2018). In another study, Bar-Kalif and colleagues 
(2015) compared patient and clinician report on patient’s functioning over treatment and found 
clinicians varied in over- and underestimating their patients’ functioning without a consistent 
pattern. Roughly half of clinicians were more likely to overestimate patient’s functioning, while 
others underestimated with great variability across patients. It was only after clinicians were 
granted access to their patients’ own reports did clinician report begin to align with their patient’s 
(Bar-Kalif et al., 2015). According to scores at the end of treatment, patients who improved the 
most were seen by clinicians whose reports became more accurate earlier in treatment (Bar-Kalif 
et al., 2015), suggesting that feedback from patients helps clinicians more accurately gauge patient 
trajectories and perhaps become more effective providers. 
MacDonald and Mellor-Clark (2015) reviewed the social psychology literature and suggest 
that clinician judgement often falls short because individuals cannot accurately assess their own 
performance. Expert intuition is more likely to be accurate in “high validity environments,” or 
settings where regularities in behavior are common and expertise is built through experience (p. 
251). Statistics and actuarial predictions have been found to outperform experts in irregular 
environments because of the consistent attention and weight assigned to cues and data. Clinical 
settings are thought to be irregular, or “low validity environments,” where clinician blindsided-
ness should be expected and attended to openly (MacDonald & Mellor-Clark, 2015, p. 252). The 
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expectation that clinicians should be able to remember each patient’s state at intake and quickly 
make comparisons at each time point throughout treatment is unreasonable at best (Hatfield et al., 
2010). Acceptance that clinicians are being asked to do the impossible opens the door for the 
introduction of more precise methods that have been proven to make prediction possible. For 
instance, the methods embedded into progress monitoring and feedback platforms are empirically-
derived and provide expected response curves for each individual patient based on severity at 
baseline (Lambert et al., 2002a). 
The current proposal describes progress monitoring and feedback, a type of intervention 
that has demonstrated empirical support for improving patient outcomes across a variety of 
settings. Originally conceptualized as a quality assurance effort, the intervention has been 
theorized to personalize a clinician’s practice to promote patient engagement and prevent treatment 
failure. Progress monitoring and feedback is delivered through a measurement feedback system, a 
web-based platform that has the ability to guide treatment planning quickly and efficiently for the 
clinician. The proposed study involves a program evaluation of a commercialized measurement 
feedback system that was adopted agency-wide by one large community mental health center. Its 
impact on premature dropout and treatment length in addition to rate of symptom change was 
examined. Findings contribute to the implementation science research base through replication of 







 This chapter begins with an overview of mental health service in the United States and the 
costs associated with access and utilization of care over time. An approach to improving the 
practice of psychology follows. The progress monitoring and feedback literature and meta-
analyses on the efficacy and effectiveness of measurement feedback systems (MFSs) conducted 
with adult populations across various mental and behavioral health settings will be reviewed. Next, 
the handful of studies that have examined MFSs among youth populations will be discussed 
thoroughly. Methodological issues from adult and child studies will be described in order to 
contextualize interpretations and the applicability of findings to real world settings. Lastly, the 
chapter addresses the major theorized mechanisms of change associated with progress monitoring 
and feedback interventions. A case will be made concerning the utility and cost-effectiveness of 
MFSs for community mental health settings and the potential value they represent to stakeholders.  
State of Affairs of Mental Health Services in the United States 
 SERVICE UTILIZATION. Over one-third of children and one-fourth of adolescents meet 
diagnostic criteria for a psychological disorder within any given year (Costello et al., 2003; 
Costello et al., 2014). The American Psychiatric Association and American Academy of Child and 
Adolescent Psychiatry have both stated that outpatient psychotherapy should be the first line of 
treatment for the majority of youth who present with significant psychological distress (Birmaher 
& Brent, 2007; Connolly & Bernstein, 2007). Sadly, 77% of youth who meet criteria for one or 
more psychological disorder never access this type of care (Costello et al., 2014). Costello and 
colleagues (2014) found that within a nationally representative sample of 10,148 families, 
adolescents were more likely to have received mental health services from their school or general 
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medical practitioner than a specialist with disorder-specific training. Even for teens with three or 
more psychiatric diagnoses, less than half had received mental health services from an outpatient 
mental health facility. Youth were most likely to have accessed care if they were male, had a 
disruptive behavior disorder, or came from a single parent household classified as low income, to 
whom mental health services were provided through juvenile justice, alternative school placement, 
or special education (Costello et al., 2014).  
COSTS OF CARE. Disorders associated with mental and behavioral health, including 
substance use and abuse disorders, are often referred to as chronic diseases based on their pattern 
of service use over a lifespan (Centers for Disease Control and Prevention [CDC], 2016). The 
medical costs associated with caring for those with mental and behavioral health problems account 
for 86% of the nation’s total health care costs, estimated as $2.9 trillion each year (U.S. Department 
of Health and Human Services [DHHS], 2017, p.159). In one of the most recent congressional 
budget requests proposed to the CDC by DHHS (2017), statistics such as these precede further 
written justification for a $50 million dollar increase to designate to mental health initiatives. The 
initiatives consist of plans to increase infrastructure for improving physical access to mental health 
care for children and adults (DHHS, 2017).  
An increase in number of mental health clinics may have been requested because in the 
United States, one of the largest growing health trends is the number of emergency department 
(ED) visits for mental health related concerns (CDC, 2016; Simon & Schoendorf, 2014). Between 
2006 and 2011 alone, the number of ED visits and hospitalizations for youth with injuries unrelated 
to mental health stabilized. In contrast, the rate for those who presented to the ED primarily with 
a mental health concern increased significantly by 21% (Torio, Encinosa, Berdahl, McCormick, 
& Simpson, 2015). The largest increases in ED visits were observed among boys aged 5 to 9 years 
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old with suicidal ideation (88% increase), and 1- to 4-year-olds with behavioral issues (61% 
increase). Inpatient hospitalizations due to suicidal behavior and self-injury amongst children 
increased by 104%, with the most dramatic spike (151%) observed amongst 10 to 14-year-olds 
(Torio et al., 2015).  
Unsurprisingly, costs associated with mental health care have increased over time, 
approximately by 5 times the amount in millions spent in 1986 (CDC, 2016). For instance, from 
2009 to 2014, estimates approximated a 22% increase (i.e., roughly 145 million to 186 million) in 
health care expenditures due to mental health treatment alone (operationalized as inpatient, 
outpatient care and prescription drug costs), excluding substance abuse treatment (CDC, 2016). 
By far, the largest increase was noted for outpatient care. This is not due to, for example, greater 
allocation of Medicaid dollars to outpatient clinics, but rather because greater and more varied 
services are being provided by ED facilities and intensive outpatient hospital programs, redesigned 
to lessen the burden traditionally shouldered by inpatient hospitals. Furthermore, in the review 
conducted by Torio and colleagues (2015), 90% of children who presented to the ED between 
2006 and 2011 were labeled as “treat and release,” meaning these families were sent home after a 
brief assessment found them not at risk to themselves or others. Children with a mental or 
behavioral health concerns were estimated to visit the ED 2.6 more times in one year, versus less 
than one more time (0.6) by the children who first presented without a mental health complaint 
(Torio et al., 2015). Medicaid absorbed the majority of these costs (CDC, 2016; Holder, Rogers, 
Peterson, & Ochonma, 2017; Torio et al., 2015), which today would approximate to $2,067 per 
child per visit, without adjusting for rise in health care costs separate from inflation.   
Taken together, statistics may lead one to draw the following inferences. First, the large 
majority of children who present to the ED with mental or behavioral health problems exhibit a 
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level of severity that translates to a low level of clinical concern (i.e., does not indicate 
hospitalization or further action from a health professional). Second, these cases make up a subset 
of children who are likely to return the ED within the same year for similar reasons. These cases 
could be received and treated without the higher costs associated with accessing a hospital system, 
such as by an outpatient provider with specialized training. This way, families’ problems are 
addressed and monitored, lowering the likelihood of a crisis event where parents present to tertiary 
levels of medical care. A more preventative approach to care such as this is not a novel solution, 
as reviews of the literature have long documented the savings in costs with outpatient care versus 
hospitalization for mental health specifically (Gabbard, Lazar, Hornberger, & Spiegel, 1997; 
Leslie & Rosenheck, 1999).  
 STATE OF MENTAL HEALTH SERVICES FOR YOUTH. The cost saving benefits of outpatient 
psychotherapy extend to children, as well, as its use has been found to lead to a lower rate of 
medical service utilization (Gabbard et al., 1997). Therefore, to many, the answer for reducing 
psychological suffering is to increase the amount of mental health service providers and outpatient 
clinics, under the assumption that greater availability will reduce need (DHHS, 2017; Holder et 
al., 2017). Others have requested that attention be paid first to our nation’s current state of service 
provision and question whether increasing the quantity of providers will be sufficient (Bickman & 
Noser, 1999).  
The most recent meta-analysis of psychological therapies for youth reviewed 447 
randomized controlled trials (RCTs) that included 30,431 youth (Weisz et al., 2017). Results 
concluded that for children with anxiety (d = .61) and conduct problems (d = .46), efficacious 
treatments have been developed (Weisz et al., 2017), as well as specific practice elements that 
likely correspond to the mechanisms of change within these treatments (Bearman & Weisz, 2015; 
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Chorpita, Daleiden, & Wesiz, 2005). Unfortunately, the most robust practice elements of 
psychological treatments for youth have consistently been found to be absent from treatment-as-
usual, or the type of services delivered in community settings (Borntrager, Chorpita, Higa-
McMillan, Daleiden, & Starace, 2013). For example, studies of children treated in usual care for 
anxiety and disruptive behavior problems (the most common reasons for referral), have noted that 
evidence-based practice elements (e.g., exposure for anxiety) were absent in approximately 80% 
of individual therapy sessions (Borntrager et al., 2013; Garland et al., 2010).  
Although the research on mental health treatment for youth has helped to develop disorder-
specific treatment strategies that work, the deployment of these treatments to real world settings 
has been much less successful. Patients treated in efficacy studies also hardly match the 
characteristics of the children who are referred for services in community settings (Bearman & 
Weisz, 2015; De Haan, Boon, De Jong, Hoeve, & Vermeiren, 2013). These youths have more 
comorbid and severe symptom profiles and face various environmental barriers compared to 
children recruited in controlled trials (Bearman & Weisz, 2015; Borntrager et al., 2013; Costello 
et al., 2003). Differences may account in part for the low average rate of recovery documented 
throughout the literature (Bickman, 2008; Cooper et al., 2013; Smith & Jensen-Doss, 2017; Warren 
et al., 2010), and that 45-60% of children who enroll into outpatient services drop out before 
treatment completion (De Haan et al., 2013). Efforts toward increasing access to care are unlikely 
to help improve outcomes if the services provided are ineffective (Bickman, 2008), and unable to 
retain those who present for care (De Haan et al., 2013). In other words, more practitioners and 
greater availability of services may not make a discernable reduction in the psychological suffering 




IMPROVEMENT OF SERVICES. An alternative approach to addressing the high cost of low 
impact care is improving the quality of services delivered through existing outpatient settings. 
According to the National Committee for Quality Assurance, health care is improved through a) 
identification of standards, and b) development of performance measures. Once combined, 
comparisons between standards and performance allow accountability as areas for improving 
practice are illuminated. Quality assurance was first introduced for mental health care as the 
continuous quality improvement (CQI) approach (Bickman & Noser, 1999). CQI includes the 
assumption that a link exists between care processes and patient outcomes, and data collected from 
patients over time informs a clinician’s psychotherapeutic practice. Once a clinician adopts a new 
skill, measuring its benefit through patient report is believed to support the clinician’s permanent 
adoption of that skill for future practice (Bickman & Noser, 1999).  
“Patient-focused” research emerged to evaluate the processes involved with CQI, where 
individualizing treatment to each patient is thought to improve mental health care (Lambert et al., 
2002a; Sapyta, Riemer, & Bickman, 2005). This shift within the research field was a conscious 
one and rose from a concern that years spent promoting empirically supported treatments (ESTs) 
may have led to the misperception that mental health care services should be standardized in real 
world settings and perfectly match efficacy trial conditions (Ng & Weisz, 2016; Sapyta et al., 
2005). The decision to begin to adhere to a patient-focused approach for research and practice did 
not signify a break from ESTs, but instead a collective response to work toward delineating a path 
for translating research findings to individual cases (Bearman & Weisz, 2015; Lambert, 2015; 
Weisz, Nelson, Burlingame, & Mondragon, 2012). One of the most promising ways to personalize 
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care includes the systemized use of progress monitoring and feedback, in conjunction with practice 
elements supported by the evidence base (Bearman & Weisz, 2015; Ng & Weisz, 2016). 
PERSONALIZATION OF CARE. Over a decade ago, the APA Presidential Task Force (2006) 
published a report that defined and described the evidence-based practice (EBP) of psychology. 
Within the report, authors outlined the vantage of science-informed care and acknowledged that 
there will be many patient problems and clinical situations where the available evidence does not 
discern a specific approach. Psychologists must use clinical judgement and acquired expertise in 
such circumstances (APA, 2006). Clinical expertise is achieved through developing competencies 
that permit one to interpret the evidence and apply the best available solution to an ambiguous 
situation. Since this process will always involve probabilistic inferences, “ongoing monitoring of 
patient progress and adjustment of treatment as needed are essential to EBP of psychology” (APA, 
2006, p. 276). In this report, clinician’s use of a measurement feedback system to inform practice 
became an evidence-based practice element. 
Measurement and Feedback Systems 
“Progress monitoring and feedback” is an intervention strategy that involves two processes: 
a) the repeated collection of patient-reported information relevant to treatment processes and/or 
psychological symptoms, and b) a composition of these data that are fed back to the clinician 
systematically and intermittently over an episode of care. “Progress monitoring and feedback” is 
a phrase synonymous with “feedback-informed treatment,” “routine outcome monitoring (ROM),” 
and derivatives of these (e.g., “patient reported outcome measures” [PROMS]). It also represents 
the core intention of a measurement feedback system (MFS) (Edbrooke-Childs, Wolpert, & 
Deighton, 2016). Reference to an MFS adds specificity to the way in which data are collected and 
formatted into feedback for clinicians, through use of measurement tools that are, “administered 
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regularly throughout treatment to collect ongoing information about the process and progress of 
treatment, then provide[s] an automated presentation of the information… to mental health 
providers about their cases” (Lyon, Lewis, Boyd, Hendrix, & Liu, 2016, p. 442). Using an “MFS” 
is how progress monitoring and feedback is most commonly referred to in the United States, where 
emphasis is more often placed on the system that delivers the feedback. “ROM” and “PROMS” 
are used more frequently in the United Kingdom where measurement is the primary focus 
(Edbrooke-Childs et al., 2016).  
For simplicity, “use of an MFS” will be used to refer to the entirety of literature that has 
examined the impact of progress monitoring and feedback as an intervention strategy in 
psychotherapeutic practice. Lyon and colleagues (2016) define an MFS as a “digital technology” 
where input and presentation of patient data is done through a commercialized platform that can 
be embedded into an electronic medical system or stand alone as an online and cloud-based entity 
(p. 442). It is important to note that the majority of studies that make up the progress monitoring 
and feedback literature have not used digital technology, especially older studies that employed 
less innovative and costly methods to monitor progress and deliver feedback. However, to be 
included in the current study’s review, feedback must include data from past sessions and 
consolidated into graph form allowing simple and efficient analysis of patient progress. Some 
MFSs follow a graph with a set of recommendations intended to guide the next session (Lambert, 
Hansen, & Harmon, 2010), but this feature is not always included.  
In summary, an MFS intervention includes both a systemized platform (digitized or non-
digitized) and a patient-clinician process, for the purposes of the current study’s review. Patients 
complete standardized questionnaires that are then consolidated into a graph that communicates 
patients’ progress since treatment began, in real time, to the provider. The feedback platform 
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viewed by the clinician is often called a “dashboard” and may include additional features such as 
highlighted critical items endorsed by the patient (e.g., suicidal ideation), alerts or flags that 
communicate concern about the patient’s status, and/or recommendations for next steps in 
treatment. Ultimately, the clinician decides whether and how often to access this information. See 
Figures 1-4 for exemplars of each of these components from one digitized MFS. 
MFS EFFICACY AND EFFECTIVENESS. The act of progress monitoring and feedback has 
been stated to be an integral component of an evidence-based approach to therapy (APA, 2006), 
and is also listed as a “demonstrably effective” element of therapy relationships by the APA Task 
Force on Evidence-Based Therapy Relationships (Norcross & Wampold, 2011, p.127). Aside from 
these standards, progress monitoring and feedback represents an intervention strategy that does 
not belong to a specific theoretical orientation nor holds allegiance to any faction of therapeutic 
practice. Even without use of an EST, MFS use has demonstrated to improve treatment outcomes 
through “adapt[ing] psychotherapy to the particulars of the individual patient but do[ing] so 
according to generalities identified by research” (Norcross & Wampold, 2011, p. 131). The large 
majority of MFS studies that have been conducted include adult patients (Lambert & Shimokawa, 
2011; Shimokawa, Lambert, & Smart, 2010; Lambert, Whipple, & Kleinstäuber, 2018). Within 
the last decade, studies conducted with youth as participants have emerged, heeding the 
recommendations set forth by the preceding adult research on study design and MFS technologies.  
Mean improvement in outcome scores. Shimokawa and colleagues (2010) reviewed 6 
RCTs that evaluated the effects of providing feedback to clinicians through repeated collection of 
the Outcome Questionnaire-45 on client outcomes (Lambert et al., 1996; Lambert et al., 2010). 
Participants were university college students who were randomized either to receive regular 
psychotherapy or psychotherapy with an MFS, and clinicians were doctoral trainees. Those in the 
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feedback condition experienced a significant reduction in distress and increased odds of 
improvement from baseline to the last treatment session compared to patients whose clinicians did 
not receive feedback (d = .12) (Shimokawa et al., 2010). Knaup, Koesters, Schoefer, Becker, & 
Puschner (2009) reported similar findings in their review of 12 studies that both included RCTs 
and non-randomized designs. Feedback effects were reported to be larger when both clinician and 
patient received feedback on patient progress (d = .30), compared to when only the clinician 
received feedback (d = .09). Methodology concerning what constituted an MFS varied greatly 
across studies (Knaup et al., 2009), compared to the former review (Shimokawa et al., 2010), 
which only included studies that utilized the same patented MFS.  
 A more recent review that included 12 RCTs returned more tempered results for effects of 
an MFS on mean score improvement (Kendrick et al., 2016). The review included studies from 
both mental health and primary care settings, and three studies from Shimokawa and colleagues 
(2010) that met researchers’ criteria for randomization (Kendrick et al., 2016). A significant effect 
of feedback on outcome scores was not found, with authors acknowledging the difficulty in making 
comparisons due to the heterogeneity across studies. Authors did find that when more severe 
patients were extracted from samples and analyzed separately, MFS use did significantly improve 
outcomes by the end of treatment (d = .22) (Kendrick et al., 2016). Thus, the effects of an MFS 
were significant for the most severe patients (who also face the highest risk of premature drop-out) 
but less detectable for patients who began treatment with more mild concerns or respond to 
treatment as expected early on (Kendrick et al., 2016). This finding has been reported by others as 
well (Gondek, Edbrooke-Childs, Fink, Deighton, & Wolpert, 2016; Lambert et al., 2003). 
 Another cumulative review comprised of 32 studies used a broader and more inclusive 
definition of an MFS and reported similar findings (Gondek et al., 2016). More severe and 
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intractable patients were more likely to benefit from their clinicians’ usage of progress monitoring 
and feedback when compared to less severe counterparts and all patients within a control condition, 
as found in 73% of their sample of studies (Gondek et al., 2016). Importantly, not only does 
severity at intake predict improvement in response to feedback (Janse, De Jong, Van Dijk, 
Hutschemaekers, & Verbraak, 2017; Smith & Jensen-Doss, 2017), but patients who exhibit an 
unexpected pattern of response to treatment are also more likely to benefit from their clinician 
receiving feedback (Gondek et al., 2016; Lambert et al., 2003; Shimokawa et al., 2010). Patients 
who either do not improve at a rate expected given their initial score at baseline or begin to 
deteriorate further from baseline are categorized as “not-on-track” (NOT) or “off-track,” as they 
are at the highest risk for dropping out of treatment before their symptoms improve (Lambert et 
al., 2003; Shimokawa et al., 2010). Many MFSs include an embedded signal-alarm protocol that 
deploys electronic and color-coded notifications that alert clinicians to NOT patients (Delgadillo 
et al., 2017; Lambert et al., 2010; Lucock et al., 2015).  
Treatment efficiency. For community care settings, treatment length and number of 
sessions is often a variable of interest due to the need to prioritize cost-effectiveness (Bickman & 
Noser, 1999; Brown & Jones, 2005; Kendrick et al., 2016). Many studies include average number 
of sessions as an outcome variable for an entire sample, but measurement of actual treatment 
efficiency, opposed to treatment length, has been thought to require different conceptualizations 
for NOT and “on-track” (OT) patients (Gondek et al., 2016; Lambert et al., 2003). NOT patients, 
due to their severity and unpredictability, are encouraged to remain in treatment until they improve. 
OT patients (i.e., those who respond to treatment as expected) typically require a less intensive 
program of care with fewer sessions to reach improvement status, compared to NOT patients 
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(Lambert et al., 2003). For the OT subgroup, more sessions do not predict a higher likelihood for 
improvement as they do for the NOT subgroup (Delgadillo et al., 2017).  
Lambert and colleagues (2003) reviewed three seminal studies and concluded that feedback 
not only provided value to all patients who present for treatment, but that clinician use of an MFS 
makes treatment more efficient. OT patients in the feedback condition received approximately a 
single session less than the amount received by OT patients in the control condition. NOT patients 
in the feedback condition received 1 to 1 ½ more sessions than NOT patients in the control 
condition (Lambert et al., 2003). Authors concluded that feedback benefits NOT patients by 
keeping them in treatment longer in order to experience improvement, and OT patients benefit 
through shortened treatment episodes (Lambert et al., 2003). The differences due to condition led 
Lambert and colleagues (2003) to further infer that if clinics took advantage of an MFS for OT 
patients, clinicians would be able to terminate earlier with these patients, and shorter treatment 
episodes for this subgroup would compensate for the additional costs associated the NOT subgroup 
(not accounting for the costs absorbed by other care providers).  
Lambert and colleagues’ (2003) findings have been replicated (Gondek et al., 2016; Janse 
et al. 2017; Kendrick et al., 2016). Janse and colleagues (2017) conducted a longitudinal study 
with historical controls in a community setting where an MFS was implemented at midpoint with 
1,006 patients and 85 therapists participating. Significantly more patients who enrolled into 
services after the MFS was implemented clinically improved within the first five sessions of 
treatment (Janse et al., 2017). The OT subgroup, particularly those diagnosed with depression 
versus any other disorder, also received two fewer sessions per treatment episode than did the 
matched controls who were served prior (Janse et al., 2017). Across the studies that report more 
sessions for NOT patients, they also report that all patients in a feedback condition benefit (OT 
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patients included) from use of an MFS compared to patients in a control condition (Gondek et al., 
2016).    
Delgadillo and colleagues (2017) examined the effects of an MFS+ condition versus an 
MFS already in use within a community care setting on treatment efficiency. In this study, the 
MFS was defined as the repeated collection of two short measures for depression and anxiety 
which were then electronically fed back to the clinician in graph form. The experimental condition 
(MFS+) included the addition of expectancy curves to signify OT status and alarm-signals to the 
clinician for when a patient became NOT (i.e., features often included in a basic MFS condition in 
other studies). Average cost of treatment was reported to be significantly higher for those in the 
control condition compared to patients in the MFS+ condition (Delgadillo et al., 2017). Authors 
inferred that higher cost related to the greater number of sessions for patients in the control 
condition, because clinicians did not have a reliable method for assessing progress and whether a 
patient should to be referred to upper level care (Delgadillo et al., 2017). Providing expectancy 
curves to clinicians to help detect individual treatment status may drive an MFS’s impact on 
treatment efficiency. Although Delgadillo and colleagues’ (2017) study does not provide a clear 
picture of treatment efficiency (a non-MFS control condition was not included), it does move the 
literature toward illuminating potential mechanisms for cost effectiveness.   
Rate of recovery. In addition to symptom reduction and treatment length, the rate in which 
a patient reaches improvement status is relevant for judging the utility of an MFS. In one study 
conducted in mostly private practice offices, clinician use of an MFS did not affect symptoms 
overall, but it did associate with a faster rate of recovery (De Jong et al., 2014). In this case, 
feedback was delivered to both clinician and patient, not just to the clinician (De Jong et al., 2014). 
Similarly, in a community mental health care setting, Janse and colleagues (2017) found that 
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significantly more patients in the MFS condition achieved reliable positive change within the first 
five sessions of treatment, compared to those in the control condition (Janse et al., 2017). 
Additionally, one RCT conducted with university college students found that patients with 
clinicians assigned to the MFS condition reported larger gains in therapeutic alliance earlier in 
treatment than did patients in the control condition (McClintock et al., 2017). The use of an MFS 
may not only move a patient faster to recovery, it may also help foster the development of the 
therapeutic relationship.  
Dropout prevention. The dropout rate for youth in community settings has been estimated 
to be 45%, according to clinician report (De Haan et al., 2013). Through use of an MFS, clinicians 
have the ability to predict whether an adult patient will stay in treatment and potentially later 
improve or deteriorate and preemptively drop out of treatment (Kendrick et al. 2016; Shimokawa 
et al., 2010). There is reason to believe these findings could extend to youth in treatment, as well. 
For instance, one sample of 2,310 youth were seen by 115 clinicians across one community mental 
health setting and one managed care setting (Warren, Nelson, Burlingame, & Mondragon, 2012). 
Approximately half of the sample ended treatment without significant improvement in symptoms, 
with fewer patients improving if treated in the community setting (Warren et al., 2012). If the same 
measurement tool used in the study also fed results back to each clinician in real time (instead of 
just being collected), 19% of the youth served in the community mental health care settings and 
13% in the private practice settings that were deteriorating while in treatment would have been 
detected by their clinicians (Warren et al., 2012). With access to patient feedback, it is possible 
that dropout could have been prevented. Systemized feedback to clinicians has great potential to 
improve psychotherapeutic practice and retain those who are not progressing in care. 
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MFS EFFICACY AND EFFECTIVENESS IN YOUTH POPULATIONS. In order to assess whether 
the benefits of an MFS could transfer to youth, Bickman, Kelley, Breda, de Andrade, & Riemer 
(2011) conducted a multi-site RCT with 340 youth. Community mental health clinics that 
expressed interest in participating (n = 28) were randomized to one of two conditions: an active 
condition where patient outcome data was fed back to clinicians, or a control condition where 
clinicians only received a summary of patient progress every 90 days (Bickman et al., 2011). 
Clinicians in the feedback condition received patient data within one to two weeks after collection 
and also received a summary of progress over the previous 90 days. Repeated measurement of 
youth symptoms and functioning was collected using clinician, child, and parent report at the end 
of each session. Data were collected via paper and pencil, which then researchers uploaded an 
electronic MFS, called the Contextualized Feedback System (Bickman et al., 2011).  
Bickman and colleagues (2011) found that youth were more like to improve from baseline 
at a significantly faster rate if their clinician received more frequent feedback, according to youth 
(d = .18), clinician (d = .24), and parent report (d = .27). According to intent-to-treat analyses, 
effects continued to remain significant according to youth and clinician report but not for parent 
report. Interestingly, a significant dose-response relationship between number of feedback reports 
viewed by the clinician and outcomes was found (Bickman et al., 2011). The more a clinician 
viewed the patient’s feedback report, the greater the gains the patient made in treatment (Bickman 
et al., 2011). Once clinicians who never accessed the MFS (despite being assigned to the feedback 
group) were removed from analyses, effect sizes increased for MFS’s impact on rate of recovery 
according to clinician report (d = .40) and youth report (d = .27) (Bickman et al., 2011).  
Bickman and colleagues (2016) conducted another study to evaluate the effects of an 
updated version of their original MFS (Bickman et al., 2011). Youth (n = 257) were randomized 
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to the MFS or control condition within two outpatient clinics (“Clinic R” and “Clinic U”), where 
clinicians (n = 21) saw youth in both study conditions (i.e., randomization at the patient level). 
Clinicians could immediately access feedback electronically for patients in the MFS condition, 
versus every six months for their patients in the control condition. Both parents and youth reported 
a significant reduction in symptoms over the course of treatment, regardless of condition and site. 
The feedback effect was significant according to clinician report at Clinic R but not at Clinic U 
(Bickman et al. 2016). At Clinic R, the dose-response relationship among clinician access to 
feedback and symptom improvement (Bickman et al., 2011) was found to be significant for to 
clinician and youth report (Bickman et al., 2016), i.e., the more clinicians viewed the feedback, 
the greater an effect it had on improvement. Implementation was found to vary greatly across the 
two sites, which opened questions related to treatment integrity (Gleacher et al., 2016). Differences 
across sites included administration procedures, stakeholder buy-in, and level and type of ongoing 
consultation and supervision (Gleacher et al., 2016). This highlighted the importance of MFS 
integrity, specifically adherence, discussed next. 
ADHERENCE TO THE MFS. In an attempt to quantify the differences across the two sites, 
Bickman and colleagues (2016) developed a composite variable to reflect the amount of 
intervention dosage received by the clinician (i.e., dose-response relationship), and called it the 
Implementation Index. The index equaled the number of times a clinician accessed feedback via 
the electronic MFS divided by the total questionnaires completed for a given case (Bickman et al., 
2016). Although the index does not quantify how feedback was used by the clinician, it provides 
a unit related to MFS engagement that can be used to compare clinicians to each other by 
calculating the degree to which the MFS was accessed. On average, the indices for clinicians at 
Clinic R averaged 25% higher than indices of clinicians at Clinic U (Bickman et al., 2016). More 
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interestingly, analyses showed that if a clinician adhered to the intervention and accessed the MFS 
at a rate of 75% or above, the effect sizes would have increased to .70 (according to youth) and 
.80 (according to clinician), respectively, only after 10 weeks of treatment (Bickman et al., 2016). 
Thus, the more clinicians access the MFS, the more patients benefit. Clearly, clinician behavior 
greatly affected outcomes, as seen in past studies with adult patients (Amble et al., 2015; De Jong, 
van Sluis, Nugter, Heiser, & Spinhoven, 2012; Lutz et al., 2015). 
Bickman and colleagues (2011) provided some support that children and adolescents 
benefit when an MFS is combined with standard treatment-as-usual delivered by community 
providers. Both studies highlighted that the presence alone of an MFS or merely the repeated 
collection of data is not enough; clinicians must access the feedback in order for an MFS to add 
value to practice (Bickman et al., 2011; Bickman et al., 2016; Kendrick et al., 2016). 
Approximately 35% of clinicians assigned to the feedback condition in Bickman and colleagues’ 
(2011) study did not access the feedback reports. The clinicians who did were found to discuss 
relevant symptoms in following sessions with patients more often (Kelley, de Andrade, Bickman, 
& Robin, 2012) and addressed specific problem areas faster than clinicians in the control condition 
did (Douglas et al., 2015). For example, an adolescent who endorsed recent substance use led to 
the MFS issuing a warning signal to the clinician. This topic was then more likely to be brought 
up and discussed with the adolescent, according to the clinician, during a following session 
(Douglas et al., 2015). When a crisis of any kind was reported and fed back to the clinician, the 
treatment processes and symptoms related to functioning were more likely to be discussed in a 
following session (Kelley et al., 2012). Whether it was the clinician or the patient who broached 
the topic in session cannot be determined, but session content individualized to patient was not 
reported by clinicians without access to feedback (Douglas et al., 2015; Kelley et al., 2012).  
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The State of the Evidence for MFSs 
 The progress monitoring and feedback literature for mental health practice has progressed 
greatly over the past ten years with advancements in data collection innovation and feedback 
efficiency. But unlike an EST that is first developed, manualized, and then tested through efficacy 
trials, progress monitoring and feedback as an intervention strategy does not have a list of criteria 
that establishes it as a distinct entity from other intervention strategies. Even though standards have 
been promoted (Lyon et al., 2016), any kind of monitoring and feedback procedure is permitted to 
be called and tested as an “MFS.” Because of this, interventions within the studies that make up 
this literature vary greatly (Bergman et al., 2018; Kendrick et al., 2016). Without agreement, it is 
challenging to compare different MFS systems and confidently interpret the findings (Carlier et 
al., 2012; Gondek et al., 2016; Knaup et al., 2009). The most significant differences lie in feedback 
conceptualization and data collection method.  
 FEEDBACK DEFINITIONS. For the purposes of the current study proposal, feedback has been 
conceptualized as a compilation of information that has been previously collected from a patient 
with the idea that the assigned clinician will find the information useful for planning future sessions 
(Bearman & Weisz, 2015; Sapyta et al., 2005). This assumption is not unanimous among the MFS 
literature, for instance, when feedback measures are used as an outcome variable in group therapy. 
Crits-Cristoph and colleagues (2010) examined the impact of a semi-automated MFS on alliance, 
substance use, and satisfaction with group therapy treatment and reported no differences across 
experimental and control conditions. Similar findings were reported in Schectman and Sarig’s 
(2016) study that evaluated an MFS with group therapy in the school setting. In both studies, 
feedback was aggregated across reporters and delivered to group leaders as an average; therefore, 
feedback was conceptualized as a marker of group process instead of an individual’s progress 
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through treatment. Additionally, though feedback was treated as a repeating variable over time, 
many patients and students provided feedback only once (Crits-Cristoph et al., 2010; Schectman 
& Sarig, 2016), meaning change over time was not connected to an individual but to the collective 
group environment. This type of feedback appears to differ from other studies mentioned up to 
this point, yet these studies and similar ones are included in cumulative reviews. 
The form in which feedback is compiled and presented to the clinician is likely to affect 
understanding and application of the information. Since the criteria for what equates feedback has 
not been defined, disagreement on which components are integral is reflected across study design 
(Kendrick et al., 2016). For instance, simply a graph of an individual patient’s progress across time 
has represented both the feedback (Reese, Norsworthy, & Rowlands, 2009a; Reese et al., 2009b; 
Stein, Kogan, Hutchison, Magee, & Sorbero, 2010) and control condition (Delgadillo et al., 2017, 
2018), as well neither conditions (Janse et al., 2017) . Feedback in some studies has been 
summarized through interactive and computerized platforms, a mode with most empirical support 
for eliciting action (Harkin et al., 2016; Kluger & DeNisi, 1996). These platforms have evolved to 
store data online, graph patient progress, and provide treatment planning guides or next step 
recommendations based on a patient’s trajectory (Boswell et al., 2015; Lambert et al., 2010).  
Some MFSs employ a varied notification system where green, yellow, and red signify 
improvement, no significant change, and deterioration, respectively, presented alongside graphs 
electronically (Lambert et al., 2010), through a traffic light design (Lucock et al., 2015), or a 
colored sticker placed onto physical patient files by researchers (Lambert et al., 2002a, 2002b). 
Connolly-Gibbons and colleagues (2015) collapsed patient categories to green and red (i.e., 
progressing as expected or not) and issued printouts to clinicians before every session. This type 
of color coding and additional notifications to clinicians for when patients go “off track” are 
 
 24 
thought to be what makes an MFS effective for patients (Delgadillo et al., 2017; Douglas et al., 
2015; Lambert et al., 2002b), but further study into the feature(s) that best facilitates feedback’s 
utility for clinicians is warranted.  
PROGRESS MONITORING PROCEDURES. Without specification on how often feedback 
should be delivered, data collection procedures vary across studies that claim to be measuring the 
same intervention approach. Patient data should be collected often and fed back immediately 
before the patient or clinician has terminated treatment (Bickman & Noser, 1999; Lyon et al., 2016; 
Sapyta et al., 2005), but this may not have been the case in some studies. Some studies have 
included a system that delivered feedback at on a fixed timetable (e.g., once a month) that was 
completely separate and unrelated to appointment schedules and data collection frequency (Brown 
& Jones, 2005; Davidson et al., 2017). Such a design proved to be insufficient, as many patients 
deteriorated and left treatment before clinicians received the feedback (Brown & Jones, 2005). 
Other feedback conditions have included designs where patients reported their progress every 5 
(De Jong et al., 2012), 10 (Warren et al., 2012), or 20 sessions (Lutz et al., 2015).  
One of the largest differences across studies involves the way in which data is collected, 
and idiosyncrasies concerning data collection have the potential to bias patient response. Indeed, 
one study found that an independent measure collected in addition to the progress measures 
administered through an MFS returned different results concerning intervention effectiveness 
(Janse et al., 2017). Janse and colleagues (2017) found that use of an MFS led to significantly 
improved symptoms according to the repeated measures that were administered to patients (n = 
1006) in front of and then immediately scored by clinicians (n = 85) at the beginning and end of 
each treatment session. Similar findings were not reflected by the secondary measure collected at 
pre- and post-study by researchers. Authors mention that the measures scored in front of patients 
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were positively skewed, i.e., the highest choice option was endorsed in succession and on average 
after the third session (Janse et al., 2017). Similar results have been found in other studies that used 
a similar MFS procedure (Reese et al., 2009a, 2009b). It is possible that other processes are being 
measured in this scenario, aside from the intervention’s impact on a clinician’s practice or patient’s 
functioning (Bergman et al., 2018; Kendrick et al., 2016).    
A clinician’s role in the data collection process differs greatly across studies. How data are 
collected is a crucial feature to mention, as procedures surrounding use of an MFS greatly affect 
clinician buy-in and its adoption when implemented with community clinicians (Gleacher et al., 
2016). Within one study, the feedback condition included one site where data was collected via 
paper and pencil and another site that permitted patients to input their data electronically (Bickman 
et al., 2016), which is often preferred because of efficiency and lower chance of data entry error 
(Hall et al., 2014; Hatfield et al., 2010; Lyon et al., 2016). Clinician responsibilities required for 
each MFS vary greatly and include scoring measures by hand and then immediately discussing 
results (Miller, Duncan, Sorrell, & Brown, 2005), faxing patient responses to researchers in real 
time (Stein et al., 2010), inputting the data themselves once the session has ended (Hatfield et al., 
2010), or delivering items out loud (Kendrick et al., 2016). When an MFS’s functionality is 
dependent upon extra work from clinicians, implementation suffers (Gleacher et al., 2016; Kotte 
et al., 2016). Though, study designs that force clinicians to attend to patient scores in any capacity 
as part of the data collection process are likely to influence intervention dosage. The intervention 
dosage is likely to be greater for clinicians involved in data collection compared to clinicians who 
must go out of their way to access data when assigned to a feedback condition (Harkin et al., 2016).  
In addition to frequent monitoring and timely feedback, the actual measures that are 
administered through an MFS deserve equal weight of evaluation (Bickman & Noser, 1999; 
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Harkin et al., 2016). Clinicians favor measures that are idiosyncratic to the patient (Bickman et al., 
2000; Jensen-Doss et al., 2017), yet broad enough to be relevant at each time point that they are 
administered (Hall et al., 2014; Sapyta et al., 2005). The majority of the measures administered 
through MFSs have been tested and standardized in prior studies, but some studies included in 
meta-analytic reviews chose to design and implement a new measurement tool for their specific 
site (Connolly-Gibbons et al., 2015; Stein et al., 2010) before psychometrics were established. 
Lastly, measures should be brief but sufficiently comprehensive to be sensitive to change over 
time (Harkin et al., 2016; Kelley & Bickman, 2009). At this time, the three most popular MFSs 
repeatedly administer measures that contain 8 to 64 items at each time point (Barkham et al., 2001; 
Miller et al., 2005; Lambert et al., 1996).  
Theoretical Explanations of Progress Monitoring and Feedback  
 Reviews of studies conclude that patients in a feedback condition experience greater 
symptom reduction than patients in a no-feedback condition (Knaup et al., 2009; Lambert et al., 
2003; Shimokawa et al., 2010). Effects of an MFS have been found to be particularly beneficial 
for patients with the highest risk for dropout from treatment (Gondek et al., 2016; Kendrick et al., 
2016). Specific characteristics that make an MFS more or less effective for clinicians and their 
patients have not been defined; thus, the active ingredient(s) of progress monitoring and feedback 
is still largely unclear. Proposed hypotheses vary widely, borrowed from adjacent philosophical 
fields and adapted for human psychology. The most widely discussed theory used to help explain 
why an MFS may be effective is the Feedback Intervention Theory (Kluger & De Nisi, 1996). In 
addition, it has been proposed that an MFS’s impact is mediated by the therapeutic alliance 
between clinician and patient (Gondek et al., 2016).    
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 FEEDBACK INTERVENTION THEORY. Developed by Kluger & DeNisi (1996), the 
Feedback Intervention Theory (FIT) describes a series of decisions an individual makes, 
consciously or subconsciously, in response to feedback. A “feedback intervention,” is defined as 
“actions taken by an external agent(s) to provide information regarding some aspect(s) of one’s 
task performance” (Kluger & DeNisi, 1996, p. 255). The basic tenets of FIT state that, a) behavior 
is based on making comparisons of feedback to one’s goals or standards, and b) an individual’s 
attention is limited, so the largest gaps are attended to for priority. When feedback is presented, an 
individual makes the choice either to adjust one’s behavior (or standard), or to reject the 
information (or reframe it). This decision is influenced by an individual’s capacity at each of the 
three levels of control: task learning level, task motivation level, and meta-task level (Kluger & 
DeNisi, 1996). The task learning level of control refers to the details and steps necessary to acquire 
a novel and specific skill. Task motivation represents the middle level that receives all incoming 
information and decides whether to send incoming information to either of the two other levels. 
The meta-task level represents thinking about the self within the context of new information. See 
Figure 5 for an illustration. 
 For example, once a clinician receives feedback delivered via an MFS, this information 
lands at the middle level, the task motivation level. If this information is expected or negative in 
nature, e.g. “therapeutic alliance is poor,” depending on the capacity at the middle level, the data 
is sent upward or downward (Kluger & DeNisi, 1996). If cognitive demands from elsewhere have 
usurped the sufficient motivation necessary to attend fully to the information, it is likely to be sent 
upwards to the meta-tasks level. There, framing effects based on an individual’s innate personality 
characteristics and past experiences determine whether the feedback is rejected and reframed to be 
more acceptable to the individual, e.g. “This information is wrong because of the way in which 
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the questions are asked; My patient did not understand the question,” (Kluger & DeNisi, 1996). 
The information could have also been sent downward to the task learning level, where upon further 
inspection the clinician is likely to accept the feedback and assess the steps necessary to address 
the issue, i.e., repair the therapeutic alliance. Theoretically, it is up to the supervisor to ensure that 
the conceptualization of the feedback, or the task details, as well as the steps to for addressing an 
issue are accurate (Sapyta et al., 2005; Tracey et al., 2014).  
 The main ideas promoted by FIT is that feedback interventions bring attention to important 
information that would normally go unnoticed, and under ideal circumstances, feedback can 
facilitate clinician learning and skill development (Kluger & DeNisi, 1996; MacDonald & Mellor-
Clark, 2015; Sapyta et al., 2005). Goldberg and colleagues (2016) sought to test whether 
implementation of a novel MFS in a community mental health setting improved the clinician 
practice over time, versus only tailoring therapy for each patient individually. Patient outcomes 
were collected across seven years from 5,128 patients and 153 clinicians (Goldberg et al., 2016). 
In order to account for turnover and the possibility that better clinicians were hired as the study 
proceeded, employment start date was included as a statistical predictor of patient outcomes. 
According to outcome scores collected pre-post, patients were found to improve at a significantly 
higher rate at the seven-year mark from when the MFS was implemented (d = 1.17), at a rate of 
0.035 of an effect size each year, and clinician start date was not a significant predictor (Goldberg 
et al., 2016). Also, patient-reported symptoms at baseline increased each year, to which Goldberg 
and colleagues (2016) inferred that although patient severity on average increased over time, 
clinicians were becoming more skilled and effective in treatment delivery. This study is the first 




THERAPEUTIC ALLIANCE. Norcross and Wampold (2011) introduced the “evidence-based 
psychotherapy relationship” in conjunction with meta-analytic evidence of the therapeutic 
alliance’s impact on psychotherapy outcomes (Horvath, Del Re, Flückiger, & Symonds, 2011). 
Within their special issue on this topic reporting the results of the APA Task Force on Evidence-
Based Therapy Relationships, common correlates of the therapeutic alliance and effective methods 
of adapting therapy were described. Along with foundational elements such as empathy, goal 
consensus, collaboration, and positive regard, collecting patient feedback through the use of 
standardized measurement tools was included as related to the development of the therapeutic 
alliance (Norcross & Wampold, 2011). Progress monitoring and feedback has been theorized to 
impact engagement and motivation for treatment (Carlier et al., 2012; Macdonald & Mellor-Clark, 
2015), and through strengthening the components that make up the therapeutic relationship, the 
use of an MFS has been theorized to prevent premature termination and lead to better patient 
outcomes (Horvath et al., 2011; Lucock et al., 2015; Norcross & Wampold, 2011).  
Unsurprisingly, one sample of 482 clinicians listed status of the therapeutic alliance as one 
of the most useful pieces of information to know when working with an adolescent patient 
(Bickman et al., 2000). More recently, researchers have been interested in how alliance may 
interact with a clinician’s use of an MFS. Studies that included measures for both alliance and 
outcomes have largely reported that symptom improvement from the use of an MFS does not 
significantly relate to (nor hinder) the therapeutic alliance (Gondek et al., 2014; Grossl, Reese, 
Norsworthy, & Hopkins, 2014; Lucock et al., 2015; Reese et al., 2009b; Schechtman & Sarig, 
2016). In one study that reported null findings concerning the effects of an MFS on treatment 
outcomes, use of the MFS was found to affect the rate of change in patient report of the therapeutic 
alliance (McClintock et al., 2017). The clinician and patient’s relationship developed faster if the 
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clinician was assigned to the MFS condition (McClintock et al., 2017), so some mechanism 
associated with the process of monitoring patient progress impacted the therapeutic alliance in a 
positive way. In summary, if a strong therapeutic alliance is a chief concern to which the clinician 
believes symptom improvement is directly tied, then the use of an MFS has only been reported to 
help facilitate its development. Likewise, MFS use also improves treatment outcomes, although 
through a seemingly separate path.  
Statement of the Problem and Purpose 
 Medical and professional care devoted to mental health treatment has become more costly 
over time, largely due to the increase of youth accessing the most expensive levels of care (e.g., 
EDs) that may be ill equipped to treat mental and behavioral problems past the acute phase (Holder 
et al., 2017; Torio et al., 2015). This trend could be explained both by poor access to outpatient 
mental health care (e.g., waiting lists for intake appointments), as well as ineffectiveness of these 
services once enrolled (Bickman, 2008). Unfortunately, none of these services at any level are 
meeting the need in proportion to its growth (Costello et al., 2014; De Haan et al., 2013). Instead 
of efforts that target quantity of outpatient mental health treatment providers, quality of these 
entities must first be addressed (Bickman & Noser, 1999; De Haan et al., 2013). The research to 
date has championed practices that emphasize the use of progress monitoring and feedback in 
practice (Bearman & Weisz, 2015; Ng & Weisz, 2016). Although the specific mechanisms that 
facilitate an MFS’s effectiveness are unknown, their use has been empirically proven to improve 
treatment outcomes, especially for intractable patients who traditionally leave treatment before 
recovery (Kendrick et al., 2016). Progress monitoring and feedback as an intervention strategy has 
been studied thoroughly in the adult literature while only a handful of studies report an MFS’s 
impact on services for youth (Bergman et al., 2018). The purpose of the current study is to 
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contribute to this section of psychological science that aims to improve our existing mental health 
care systems for youth.  
Research Questions and Hypotheses 
 RESEARCH QUESTION 1. Does a clinician’s use of an MFS impact treatment engagement 
for youth treated at a community mental health center? 
Hypothesis 1a. The use of an MFS will decrease dropout rate, and this relationship will be 
moderated by a patient’s urgency at intake. 
 Rationale 1a. Since clinicians did not have access to an MFS that monitored patient 
progress, patient symptom deterioration was quantitatively undetectable. It is possible that because 
clinicians are responsible for an overwhelming number of tasks for each patient, they may be prone 
to error when predicting individual patient treatment response (Hannan et al., 2005; Hatfield et al., 
2010; MacDonald & Mellor-Clark, 2015), and efforts to retain the patient may not have been made 
during Wave A. Urgency at intake is hypothesized to help explain the relationship between MFS 
use and dropout, since patients whose symptoms or presenting problem(s) were more severe at 
intake (versus less severe) may be more likely to drop out (De Haan et al., 2013), since pattern of 
response during treatment was not accessible in Wave A.  
 Hypothesis 1b. The use of an MFS will increase treatment length per treatment episode, 
and this relationship will be moderated by urgency at intake. 
 Rationale 1b. Patients who begin at a more severe state at intake are more likely to improve 
through a clinician’s use of an MFS versus patients who begin treatment at a lower level of 
severity, and this may be because the MFS keeps more severe patients in treatment longer (De 
Jong et al., 2014; Gondek et al., 2016; Kendrick et al., 2016; Janse et al., 2017). Access to the MFS 
may allow clinicians to make more informed decisions concerning termination of services, and 
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those who are more severe at baseline are more likely to be retained in treatment longer in order 
to reach improvement status (Brown & Jones, 2005; Cooper et al., 2013; Lambert et al., 2003). 
RESEARCH QUESTION 2. For patients whose clinicians have access to an MFS, does their 
rate of symptom change depend upon intervention dosage? 
Hypothesis 2. Patients whose clinicians access their feedback more often will improve at 
a faster rate than patients whose clinicians access feedback less often, and this relationship will be 
moderated by urgency at intake.  
 Rationale 2. A dose-response relationship among number of times a clinician views patient 
feedback and patient outcomes has been found in past studies (Bickman et al., 2011, 2016). 
Clinicians who choose to view the feedback reports delivered through the MFS may be more likely 
to deliver more personalized care. Since a control group does not exist in this study, patients are 
expected to improve over time independent of the MFS intervention, but higher MFS dosage is 
expected to associate significantly with greater treatment outcomes (Bickman et al., 2011, 2016; 
De Jong et al., 2012). Furthermore, this effect is expected to be strengthened for those who 
presented for treatment at a higher symptom severity compared to patients who are less severe at 
baseline. Since MFSs are believed to be the most effective for NOT patients (Kendrick et al., 
2016), urgency at intake is believed to moderate the relationship between intervention dosage and 
treatment outcomes, according to youth- and parent- report. Those with higher levels of urgency 
for treatment at intake are believed to have greater symptom severity and to be less likely to 







 Patient data for the current study were drawn from an electronic medical record database 
managed by one community mental health clinic (CMHC) for youth in Central Texas. The study’s 
sample (n = 538) was collected from an archival database of families (n = 1,064) that presented 
for outpatient individual therapy between February 2016 and February 2018. Inclusion criteria 
included youth with at least one legal guardian(s), hereafter referred to as “parent(s),” who attended 
at least one individual therapy session after an intake appointment conducted on-site. The child or 
adolescent had to have attended the individual session either alone or with a parent present. The 
child or adolescent had to have been between the ages of 4 to 17 years old at time of intake. The 
youth and/or parents could be English or Spanish-speaking. Parents must have also demonstrated 
a fourth-grade reading level in order to be included into the study.  
Patient characteristics. The study included two waves of patients: Wave A and Wave B. 
Participants from Wave A were not included in Wave B. Wave B patients must have ended 
treatment before the end of Wave B (February 2018). “Treatment episodes” is used to refer to a 
patient’s treatment duration where individual therapy was conducted by the same clinician on an 
intended routine schedule (e.g., once a week, once every two weeks). A treatment episode has 
ended when the patient begins a transfer procedure to a new clinician, no-shows at least twice in a 
row, or attends a termination session. Youth who presented for an intake appointment only, group 
therapy, walk-in clinic, or home-based services delivered by clinicians employed by the CMHC 
were excluded from the study.  
 
 34 
The final sample included 538 families who were served through individual therapy 
services across Wave A (n = 279) and Wave B (n = 259). Mean age at intake was 9.88 (SD = 3.90), 
57% male (n = 307). The majority of patients (51%) identified as either Latinx or Hispanic (n = 
277), 39% as White/Non-Hispanic (n = 208), 8% as Black/African American (n = 42), and 
approximately 1-2% as Asian American/Pacific-Islander or “Other” (n = 8). The majority of 
patients (84%) received care through some type of subsidized program, such as a federal or private 
grant, or government-provided insurance. See Table 2 more information on patient characteristics 
divided by wave membership. 
Clinician characteristics. A second set of participants included mental health clinicians 
employed by the CMHC between February 2016 and February 2018 (n = 49). Of these 49 
clinicians, 21 delivered services to youth in both Wave A and B. Twenty-eight clinicians delivered 
services only during Wave A or Wave B. This group is made up of mostly White/Non-Hispanic 
women (72%). Of those who were licensed (n = 37), the majority (81%) were masters-level 
clinicians. Clinicians were mostly social workers (n = 20), and the rest were trained either through 
doctoral school and clinical psychology programs (n = 18), or a counseling masters program (n = 
11). Caseload averaged across wave equaled a median of 6 patients per clinician (M = 7.70, SD = 
5.75). See Table 3 for additional clinician characteristics and separation of the above estimates 
separated according to wave.  
Procedures 
STUDY TIMELINE. The study includes two waves: Wave A and Wave B. Wave A represents 
the year between February 15th, 2016 to February 15th, 2017; Wave B represents the year between 
February 16th, 2017 to February 16th, 2018. The midpoint between the two waves is when the 
measurement feedback system (MFS) was rolled out agency-wide within the participating 
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community center and satellite school-based clinics. All clinicians were mandated to begin to use 
the MFS and administer MFS measures for all patients at this point in time, February 15th, 2017. 
All clinicians employed by the CMHC at that point in time attended a one-day training delivered 
by the MFS developers three months prior to the implementation date.  
All participants and their legal guardian(s) underwent notice of privacy and informed 
consent agreement prior to collection of protected health information and questionnaire data as 
part of standard clinic procedure. Clinic documents included notification that patient information 
may be used for quality assurance purposes. For the current study, data collection began in 
February 2018. Patient demographic data for those served between February 2016 to February 
2018 (i.e. episode of care ended prior to the implementation of the MFS) were extracted from 
Filemaker, the agency’s electronic medical record system. Questionnaire data for patients who 
were served only during Wave B (i.e. episode of care began following the implementation of the 
MFS) were extracted directly from the MFS’s cloud-based platform, the OQ Analyst (Lambert 
et al., 2010). The current study was classified as a program evaluation by University of Texas’s 
Institutional Review Board and characterized as exempt for all data collection and analyses 
procedures (Study No. 2018-01-0164). 
For patients in Wave B, measures associated with symptom severity were completed 
electronically by families once they arrived to the clinic immediately before meeting with their 
designated clinician. Both parents and youth aged 12 years or older completed a self-report 
measure on iPads provided by front desk staff. Each measure took approximately 3 to 5 minutes 
to complete. Since all data were collected electronically, clinicians were instructed to examine 
questionnaire responses via the online MFS platform immediately before beginning a therapy 
session. Clinicians were also trained by the MFS developers to use patient feedback to inform 
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clinical decision-making regarding whether a patient was progressing, or if a rupture in the 
therapeutic alliance was reported either by parent or youth.   
MEASUREMENT FEEDBACK SYSTEM. The OQ Analyst is the most widely studied online 
interactive platform that tracks patient response during ongoing mental health treatment (Lambert 
et al., 2010, 2018). The OQ Analyst is a system that administers measures and then presents 
feedback to stakeholders, suitable for clinical use regardless of a clinician’s theoretical orientation 
or plan for individual therapy (Lambert et al., 2010). Feedback reports are produced 
instantaneously after a parent or youth completes a questionnaire, allowing them to be reviewed 
by a clinician before an individual or joint session with both parent and child begins.  
The OQ Analyst provides color-coded alerts in white, green, yellow, and red to classify 
patient status at every point of measurement (Lambert et al., 2010). The system compares a given 
patient’s rate of improvement with normative, expected rates of improvements based upon samples 
of patients at the same initial level of distress. A “white” alert notifies the clinician that the patient 
is functioning in the subclinical range. “Green” alert status lets the clinician now the patient is 
improving as expected and change in treatment plan is unnecessary at that time. “Yellow” alert 
status notifies the clinician that the patient is not making expected progress, and an alternate 
treatment plan should be considered. A “red” notification means definite insufficient progress and 
chances are high that the patient will drop out of therapy before treatment ends. Patients whose 
scores generate a red or yellow alert during treatment, the case becomes classified as “NOT” (“not-
on-track”). Patient status can change from session to session, but information that informs status 




 DEMOGRAPHIC INFORMATION. Demographic information for the parent and youth were 
collected at the intake appointment through a semi-structured interview measure constructed by 
the mental health agency. The following youth-specific variables were collected: age, gender, 
ethnicity, trauma background (i.e., “Were you ever a victim to violence?” Y/N), and financial 
options (grant eligible, insurance coverage, sliding scale, pay in full). One item is scored by the 
intake clinician on a 6-point Likert scale and refers to symptom severity at intake, or level of 
urgency based on presenting symptoms (1 = “low concern/severity,” 6 = “very high 
concern/extreme severity”).  
 Youth presenting problems and major symptoms were classified at intake or after the first 
therapy session through DSM-V diagnoses, which were later included in analyses as 
“internalizing” or “externalizing” symptom profiles. Children with an “internalizing” profile 
included those diagnosed primarily with any type of anxiety or mood disorder, including 
adjustment disorders with anxiety or depressed mood. Post-traumatic stress disorders and somatic 
disorders were included in this category. The “externalizing” category included youth with one or 
more of the following diagnoses, attention-deficit/hyperactivity disorder, oppositional defiant 
disorder or conduct disorder, adjustment disorder with disturbance of conduct, and any “other” or 
“unspecified” disorder characterized by disruptive behavior. If a youth presented with a mixed 
externalizing or internalizing profile, diagnostic type was categorized based on the primary 
diagnosis listed. The majority of patients (58%) exhibited a comorbid diagnostic profile. See Table 
2 for patient data delineated by wave.  
 TREATMENT ENGAGEMENT. Classification of dropout and treatment length per treatment 
episode to reflect level of treatment engagement were collected for all patients who enrolled into 
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services and attended an intake appointment and then at least one treatment session with their 
assigned clinician. “Dropout” was defined according to recommendations set forth by De Haan 
and colleagues (2013). Patient were classified as having dropped out if they did not return to 
treatment after two “no shows” (i.e., no call, no show to scheduled appointment), or if they 
expressed desire to end treatment and refused a termination session with the clinician. If the patient 
or family member expressed desire to end treatment and attended a termination session, the patient 
was not classified as having dropped out. According to agency rules, if a family wished to return 
to treatment after a period of inactivity, the patient would have to attend another intake 
appointment, signaling the beginning of another treatment episode often with a new clinician. 
Deliberate transfer to another clinician, as in the case of a clinician leaving, counted as new 
treatment episode for one patient.  
Treatment length was measured two ways, as number of sessions and days enrolled into 
treatment. Sessions were counted if attended by either the patient or parent and did not include the 
intake appointment conducted by an intake specialist. Whether sessions were held as scheduled or 
missed including the reason why (e.g., clinician cancelled within 48 hours) was collected from 
clinician treatment progress notes and billing records. SESSIONS MOST OFTEN WERE SCHEDULED 
AT LEAST 24 HOURS IN ADVANCE BUT IMPROMPTU MEETINGS THAT LASTED 45 MINUTES OR 
MORE WERE ALSO COUNTED AS A SESSION. NEITHER PHONE CONSULTATIONS NOR MEETINGS 
WITH TEACHERS WERE INCLUDED IN SESSION COUNT. IN ORDER TO BETTER CAPTURE TRUE 
LENGTH OF A TREATMENT EPISODE, THE TREATMENT LENGTH VARIABLE WAS ALSO MEASURED 
THROUGH NUMBER OF DAYS PER TREATMENT EPISODE. IF MANY WEEKS PASSED BETWEEN 
SCHEDULED APPOINTMENTS, FOR INSTANCE, DUE TO HOLIDAYS OR CLINICIAN CANCELLATIONS, 
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SESSION NUMBER WOULD NOT REFLECT THE AMOUNT OF TIME EACH PATIENT REMAINED ON A 
CLINICIAN’S CASELOAD AND NUMBER OF DAYS IN TREATMENT WOULD.  
SYMPTOM SEVERITY. Two versions of the Youth Outcome Questionnaire-30 (Y-OQ) 
administered through the OQ Analyst were used for parent and youth self-report of symptom 
severity or level of psychological distress (Burlingame et al., 2004). The parent version is indicated 
for report of children and adolescents aged 4-17, and the self-report version can be completed for 
those aged 12-18. The Y-OQ is a shortened version of the full Youth Outcome Questionnaire (Y-
OQ 2.01; Burlingame et al., 2001), comprised of 30 items rated on a 5-point Likert scale from 0-
4 (0 = “almost never,” 4 = “almost always”). Summative scoring is used to produce a total overall 
score across six areas of emotional and behavior distress (somatic, social isolation, conduct 
problems, aggression, hyperactivity/distractibility, and depression/anxiety). Scores range from 0 
to 120, with higher scores indicating greater psychological distress. Scores at or above the 
established clinical cutoff score of 29 are considered in the clinical range for level of distress 
(Burlingame et al., 2004). The Y-OQ has demonstrated sufficient inter-rater reliability,  = .92-
.93 (Burlingame et al., 2004; Shechtman & Sarig, 2016), and sensitivity to change (.70-.80; Mosier 
et al., 2001). An additional five items related to therapeutic alliance were included at the end of 
the Y-OQ for both parent and youth to complete. The items have not undergone psychometric 
examination separate from the Y-OQ 30, and the derived data were not examined in the current 
study. See Appendices A and B for both reporter versions of the measure in paper form. 
Both measures were administered to parents and youth of at least 12 years of age before 
each individual therapy appointment. Both reports were included in separate analyses since the 
best way, or method, for measuring whether a child is experiencing full criteria for a given disorder 
is through including perspectives from multiple reporters (De Los Reyes & Kazdin, 2005). 
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Agreement between parent and child is often low, especially for patients who are experiencing 
more internalizing systems related to anxiety and depression (Cooper et al., 2013; Hawley & 
Weisz, 2002). Disagreements among parent and child are often related to how observable a 
symptom is, e.g. aggressive acts are more observable than feelings of despair, and how distressing 
or problematic a symptom is perceived to be for the child, e.g. yelling or hitting is less of a problem 
for the child than the parent who is on the receiving end (De Los Reyes & Kazdin, 2005; Hawley 
& Weisz, 2002). Different perspectives, as well as the difference between them, provides unique 
information concerning a patient’s trajectory in treatment. 
INTERVENTION DOSAGE. To measure whether change in Y-OQ scores is influenced by the 
amount of feedback the clinician received, or intervention dose, an “Implementation Index” was 
calculated (Bickman et al., 2016). The composite considers two dimensions: the amount of Y-OQs 
completed per case, and how often the clinician viewed the feedback reports for that specific case. 
The OQ Analyst can indicate whether the feedback has been accessed by the clinician but not 
what the clinician does with the feedback. Two values were computed: Y-OQ completion and 
clinician viewing rates for parent and youth respondents. Completion and viewing rates for each 
patient were then multiplied together and then by 100, to transform the value to a percentage 
(Bickman et al., 2016). Table 1 describes how to interpret the Implementation Index derived by 
the two values.  
Planned Analyses 
 PRELIMINARY ANALYSES. Correlations (r) were used to investigate associations between 
study measures. To assess differences on demographic data, independent samples t tests were used. 
For patients in the MFS condition (Wave B), symptom status from pre- to post-treatment was 
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summarized with the reliable change index (RCI; Jacobson & Truax, 1991). The RCI indicates the 
smallest change between two scores that can be considered distinguishable from measurement 
error, by multiplying the standard error of the difference between the two scores. RCI for the 
current sample was computed to be 10 points. Deterioration status is reflected when a patient 
worsens by at least 10 points compared to patient’s baseline score. No reliable change status 
reflects a change of less than 10 points. Improvement reflects patient improvement by at least 10 
points, but patient’s final score remains above the clinical cutoff score (total score of 29). Recovery 
status reflects a similar improvement of at least 10 points, but the final score falls below the clinical 
threshold (Jacobson & Truax, 1991).  
MAIN ANALYSES. Hierarchical linear modeling (HLM) was used to examine the current 
study’s empirical aims. TO MEASURE DROPOUT AND TREATMENT LENGTH, TWO SEPARATE 
MULTILEVEL MODELS WERE USED WITH PATIENTS NESTED WITHIN CLINICIANS. To measure rate 
of change in outcome scores across time for patients in Wave B only, growth curve modeling with 
a three-level repeated measures design was used WITH MEASUREMENT OCCASIONS NESTED 
WITHIN PATIENT NESTED WITHIN CLINICIANS. THE CHOICE TO USE HLM TO TEST BOTH OF THE 
STUDY’S HYPOTHESES WAS INFORMED BY THE TYPE OF DATA COLLECTED AND THE INCLUSION 
OF RANDOM FACTORS. PATIENTS AND CLINICIANS REPRESENT RANDOM FACTORS, DUE TO THE 
FACT THAT IF THE STUDY WAS REPLICATED, THE NEW SAMPLE WOULD INCLUDE DIFFERENT SETS 
OF PATIENTS AND CLINICIANS (PITUCH & STEVENS, 2015). MFS effects were conceptualized to 
correlate across clinician and clinicians’ caseloads of patients. Also, the final data set included an 
uneven number of patients and clinicians per condition, meaning sample sizes across waves 
differed as well as number of patients assigned to each clinician’s caseload. Lastly, the number of 
Y-OQs administered and collected from each patient case differed. These factors in addition to 
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obtaining a better understanding of factors that affect outcome on the basis of a number of 
independent variables, including a time variable (i.e., measurement occasions), contributed to the 
choice to use HLM (Raudenbush, & Bryk, 2002). The statistical package, HLM7 (Raudenbush, 
Bryk, Cheong, Congdon, & Du Toit, 2011), was used to run the main analyses. 
Hypothesis 1a. The use of an MFS will decrease dropout rate, and this relationship will be 
moderated by a patient’s urgency at intake. 
Analysis for hypothesis 1a. Dropout is a dichotomous dependent variable; therefore, a 
hierarchical generalized linear model, specifically a logistic multilevel regression, was chosen to 
examine whether implementation of an MFS affected probability of dropout (the odds of Y = 1). 
Logistic regression models include a specific binomial Bernoulli distribution for the dependent 
variable, a linear regression equation, and a link function [logit(p) = ln(p/(1-p)]. The last 
component transforms the dichotomous outcome variable into a continuous one called the natural 
log of the odds of Y = 1, which can be interpreted as an odds ratio for dropout for those who sought 
treatment before or after the MFS was implemented (Pituch & Stevens, 2015). The parameters in 
these equations were not provided in terms of the outcome variable, but of the underlying variate 
that is on a scale ranging from - to +, defined by the logit transformation of the logit(p) = ln 
(p/(1-p)). The logistic function transforms these predictions back into values between 0 and 1, 
which can then be interpreted as predicted probabilities of dropout according to each predictor.  
Within the logistic regression equation, dropout was coded as 1 and treatment completion 
(i.e., non-dropout) was coded as 0. Patient-level explanatory variables included condition (“wave”; 
Wave A = 0, Wave B = 1) and urgency at intake (“urgency”; i.e. proxy for severity at baseline). 
Variability between clinicians in patient-level urgency of intake was computed by averaging 
urgency by intake scores of each clinician’s caseload, representing caseload severity. Both 
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predictors were group mean centered and clinician variability across urgency of intake 
(“meanurgencyj”) was grand mean centered. Additional patient-level variables, ethnicity and 
diagnostic profile, were examined to assess whether they explained additional variance in dropout, 
as they have in past studies (De Haan et al., 2013). Both ethnicity and diagnostic profile are 
dichotomous variables and were entered uncentered. Model parameters were estimated using the 
full maximum likelihood procedure. Explanatory variables were added level by level and retained 
based on each predictor’s significance test. Variance accounted for by the grouping variable, or 
clinician, was measured with the intraclass correlation. The unconditional logistic regression 
equation is provided below. 
Level 1:  
ln (odds Y = 1) = 0j + rij 
Level 2:  
0j = 00 + u0j 
For illustration purposes, the proposed conditional model based on research question 1a 
with all predictors entered is as follows.  
Level 1:  
ln (odds Y = 1) = 0j + 1j(urgencyij - urgencyj) + 2j(waveij - wavej) + rij  
Level 2:  
0j = 00 + 01(meanurgencyj) + u0j 
1j = 10 +  11(meanurgencyj) + u1j 
2j = 20 + 21(meanurgencyj) + u2j 
 The outcome, ln (odds Y = 1), represents a patient’s dropout status for a specific clinician. 
The regression coefficient, 0j, is the mean dropout score at level 1 and transforms to an outcome 
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variable predicted by meanurgencyj when elevated to level 2. 1j is the within-patient association 
between patient urgency and dropout, then as predicted by meanurgencyj at level 2. 2j represents 
the impact of wave (i.e., “MFS’s effect”) on dropout, the relationship depending upon clinician 
meanurgencyj at level 2. The fixed effect, 00, is the average of patient-level intercepts across 
clinicians, or the dropout mean. 01 is main effect of meanurgencyj on dropout, holding wave 
constant. Another fixed effect, 10, is the average of the patient-level urgency and dropout slopes 
across clinicians, holding wave constant. 11 is an interaction variable, and if it is positive and 
significant, the effect of patient-level urgency on dropout is larger for those clinicians who serve 
patients with higher levels of symptom severity. 20 represents the difference between the two 
waves on dropout rate, holding urgency constant. 21 is another interaction variable that examines 
whether the wave effect depends on meanurgencyj. At the group level, u0j, u1j and u2j are all level-
2 residuals, assumed to have means of zero and be independent from the residual errors at the 
patient level.  
Hypothesis 1b. The use of an MFS will increase treatment length per treatment episode, 
and this relationship will be moderated by urgency at intake. 
Analysis for hypothesis 1b. For 1b, another two-level multilevel model was used to 
examine where implementation of an MFS impacted treatment length. Patient-level variables 
(level 1) were nested within clinicians (level 2). Explanatory variables included condition (“wave”; 
Wave A = 0, Wave B = 1) and urgency at intake (“urgency”; i.e., proxy for severity at baseline). 
Urgency at intake for each of one clinician’s patients was averaged (“meanurgencyj”), serving as 
a clinician-level variable to account for clinician caseload severity in treatment length, and whether 
urgency-sessions slopes vary across clinicians. Patient-level predictors were group mean centered, 
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and the clinician-level variable was grand mean centered. Full maximum likelihood was used to 
estimate unconditional and conditional models through chi-square tests of significance. Variance 
accounted for by the grouping variable, or clinician, was measured with the intraclass correlation. 
The unconditional model is provided below. 
Level 1:  
Yij = 0j + rij 
Level 2:  
0j = 00 + u0j 
 For illustration purposes, the linear model fitted with the theorized individual- and 
clinician-level predictors is provided here: 
Level 1:  
Yij = 0j + 1j(urgencyij - urgencyj) + 2j(waveij - wavej) + rij 
Level 2:  
0j = 00 + 01(meanurgencyj) + u0j 
1j = 10 +  11(meanurgencyj) + u1j 
2j = 20 + 21(meanurgencyj) + u2j 
Yij, is the outcome, a patient i’s treatment length for clinician j. The regression coefficient, 
0j, is the mean treatment length at level 1, becoming an outcome variable in level 2 predicted by 
meanurgencyj. 1j is the within-patient association between urgency at intake and treatment length, 
controlling for wave, then as predicted by meanurgencyj at level 2. 2j represents the wave impact 
(i.e., “MFS’s effect”) on treatment length, controlling for urgency at intake, and then the 
relationship becomes dependent upon clinician meanurgencyj at level 2. The fixed effect, 00, is 
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the average of patient-level intercepts across clinicians, or the session mean. 01 is main effect of 
meanurgencyj on treatment length. Another fixed effect, 10, is the average of the patient-level 
urgency and treatment length slopes across clinicians. 11 is an interaction variable, and if it is 
positive and significant, the effect of patient-level urgency on treatment length is larger for 
clinicians who serve patients with higher levels of symptom severity. 20 represents the difference 
between two waves on treatment length. 21 is another interaction variable that examines whether 
effect of wave depends on meanurgencyj. The random effect, rij,, is the within-patient residual and 
is normally distributed with a mean of zero and variance equal to σ2. At the group level, the random 
residual error term, u0j, is the deviation of a given clinician’s treatment length mean from the 
overall average of treatment lengths. u1j and u2j depict clinician variability around their respective 
parameters, also assumed to have means of zero and be independent from patient-level residual 
error. 
Hypothesis 2. Patients whose clinicians access their feedback more often will improve at 
a faster rate than patients whose clinicians access feedback less often, and this relationship will be 
moderated by urgency at intake.  
Analysis for hypothesis 2. A three-level growth curve model assessed whether intervention 
dosage (“intdos”; measured by the Implementation Index) and patient severity at intake 
(“urgency”) affected rate of symptom change for patients in Wave B. Outcomes include repeated 
measurement of symptoms reported by parent and youth; therefore, two identical models were 
designated for each reporter. Time was nested within patients (level 1), and patients (level 2) were 
nested within clinicians (level 3). Weeks from intake versus session number was used as the 
measure for Time based on previous models of best fit (Cannon et al., 2010). Time and patient-
level variables were group-mean centered, and the clinician-level variable was grand-mean 
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centered. Time was group-mean centered because patients did not begin treatment at the same time 
but at various times throughout the year, causing each time point to be specific to each case (e.g., 
time point 2 did not represent another patient’s time point 2), causing the intercept to represent 
average mid-treatment scores. Since only patients from Wave B were included, mean improvement 
across treatment episodes cannot be attributed to the MFS. The slope coefficient representing the 
interaction between time and urgency at intake and intervention dosage is of main interest in the 
following analyses. For any significant interaction, simple slopes were examined for directionality. 
For both models, unconditional growth curve models that included time were first fitted to 
investigate whether symptoms changed significantly over treatment episodes. Inspection of 
individual growth curves informed whether time should be squared to reflect a polynomial 
function. Then, urgency at intake, intervention dosage, and a third interaction variable of 
“urgencyXintdose” were added at level 2. The interaction variable was constructed after group-
mean centering urgency at intake and intervention dosage and then multiplying these two numbers 
together (Aiken & West, 1991). The interaction variable was included uncentered, and urgency at 
intake and intervention dosage were group mean centered. Since membership overlapped across 
both waves for some clinicians, a control variable, clinician “cohort,” was included at level 3 
(dummy coded 0 if hired before MFS implementation or during Wave A, 1 if hired afterward 
implementation or during Wave B). The unconditional model that follows represents the model 
fitted to both parent- and youth-reported outcome data. 
Level 1:  
Ytij = π0ij + π1ijtimetij + etij 
Level 2:  
π0ij = 00j + r0ij 
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Level 3:  
00j = 000 + u00j 
The proposed conditional growth curve model with individual- and clinician-level 
predictors entered is provided below. The same structure was proposed for parent- and patient self-
reported symptoms. 
Level 1:  
Ytij = π0ij + π1ijtimetij + etij 
Level 2:  
π0ij = 00j + 01(urgencyij - urgencyj)1ij + 02urgencyXintdose2ij + r0ij 
π1ij = 10j + 11(urgencyij - urgencyj)1ij + 12(intdoseij - intdosej)2ij + 13urgencyXintdose2ij + r1ij 
Level 3:  
00j = 000 + 001(cohort)j + u00j 
01j = 010 + 011(cohort)j + u01j 
02j = 020 + 012(cohort)j + u02j 
10j = 100 + 101(cohort)j + u10j 
11j = 110 + 111(cohort)j + u11j 
12j = 120 + 121(cohort)j + u12j 
13j = 130 + 131(cohort)j + u13j 
 Assuming linear growth over one year’s time, Ytij is the outcome of patient i, of clinician j. 
Also at level 1, the intercept, π0ij, is a patient’s outcome score when time is equal to the average 
number of weeks a patient has been in treatment. π1ij is the model slope and the linear growth rate 
of the outcome. At level 2, 00j represents the mean outcome score across patients, becoming 
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conditional on the other covariates at the next level. 01j and 02j are the unique effect of urgency 
at intake and the interaction variable on mean outcome status, respectively. 10j is mean symptom 
change across patients taking into account all of the covariates. 11j is the effect of urgency at 
intake on symptom change for patient with an average intervention dose, and 12j is the unique 
effect of intervention dose on symptom change for patients with average urgency at intake. 13j 
answers whether the effect of intervention on symptom change depends upon change across 
urgency levels. The model residual at level 1 is denoted as eti and has a mean of zero and variance 
equal to σ2. The residuals at level 2 represent the variation of the individual πs around the means, 
and the variances of these distributions are denoted as σ002, for example. Level 3 coefficients and 
residual terms will be defined if enough variance exists that could be explained by inclusion of the 







 A sample of 538 youth who were enrolled into individual therapy services between 
February 2016 and February 2018 were included in the following analyses. Data were evaluated 
and found to be within normal limits with regards to outliers and degree of normality. Urgency at 
intake and youth-reported mean Y-OQ scores were not found to significantly correlate with each 
other, r = -.001, p = .974. Urgency at intake and parent-reported mean Y-OQ scores did 
significantly correlate, r = .159, p < .001. Independent t-tests revealed some differences in patient 
characteristics between Wave A and Wave B, which are detailed in Tables 2 and 3. Patients in 
Wave B exhibited significantly higher urgency at intake compared to patients who enrolled into 
services the year prior. Higher mean urgency at intake scores were also reflected in clinicians’ 
caseloads (Table 3).  
For patients in Wave B, symptom severity ratings (Y-OQ data) were available for 204 
patients (79% of all patients included in Wave B). Of these 204 patients, questionnaire data were 
collected 82% and 84% of the time before an individual session from a parent and/or a patient, 
respectively, referred to as the “completion rate.” Y-OQ scores collected at baseline were 
compared to ratings collected at the last session in order to assess reliable change across treatment 
episode. According to parent-report of patient’s symptoms (n = 203), 52% of the sample did not 
exhibit reliable change, 15% deteriorated, 15% improved, and 19% recovered, or exhibited 
positive reliable change, from pre- to post-treatment (or before dropout). According to youth-
report (n = 103), 54% did not experience reliable change, 14% deteriorated, 11% improved, and 
20% recovered. Findings are similar to what has been found in the past for youth served in 
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community mental health settings (Smith & Jensen-Doss, 2017; Warren et al., 2012), though the 
sample was less severe at intake compared to other samples in the same type of setting (Brown & 
Jones, 2005; Cannon et al., 2010). Of note, 42% of patients began treatment in the “non-clinical” 
range of the measure according to parent-report, 41% according to youth-report.  
Main Analyses 
 DROPOUT RATE. On average, dropout rate for all patients across both waves was 
approximately 45%. Forty-four percent of patients dropped out of treatment in Wave A; 46% of 
patients dropped out in Wave B. Intraclass correlation (ICC) calculations indicated that an 
estimated 7.48% of the overall variance in the model could be accounted for by differences 
between clinicians. Due to a non-significant test results for u1j, predictors were fitted to a random 
intercept model. Variance in predictor-session slopes across clinicians had to be held constant; 
therefore, covariance of means and slopes could not be obtained. Dropout was not found to differ 
across waves (B  = 0.01, p > .05, CI: .701, 1.454), nor did level of urgency at intake help to explain 
a significant portion of variance in dropout (B  = 0.11, p > .05, CI: 0.940, 1.321). Due to these 
results, the level 2 predictor (meanurgency) was not added to the model.  
 Following De Haan and colleagues’ (2013) recommendation, diagnostic profile and race 
were added together into the unconditional model to assess whether they could explain any 
variance in dropout rate for the sample as a whole. Diagnosis type was included as a dichotomous 
variable, distinguishing between patients with an internalizing diagnostic profile (e.g., disorders 
related to anxiety and depression, coded as 0) and patients with an externalizing diagnostic profile 
(e.g., disorders related to behavioral dysregulation, coded as 1). Race was included as a count 
variable that included frequencies of racial identity collected via parent report at intake. 
White/Caucasian patients (n = 218) were coded as 1, Latinx/Hispanic patients (n = 277) as 2, 
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African American patients (n = 42) as 3, Asian American patients (n = 3) as 4, and patients who 
indicated “Other” (n = 5) as 5. 
Diagnostic profile type significantly explained variance in dropout rate for the entire 
sample (B = 0.41, p = .033, CI: 1.034, 2.207), controlling for race. For patients with an 
externalizing diagnostic profile, the odds ratio for dropout was 1.54 times the odds of internalizing 
patients dropping out of treatment. Probabilities of dropout for externalizing and internalizing 
patients were estimated to be 50% and 42%. Additionally, race/ethnicity was found to significantly 
account for unique variance in dropout rate (B = 0.43, p < .001, CI: 1.227, 1.942), above the 
variance accounted for by diagnostic profile. Differences in dropout rate amongst White/non-
Hispanic (n = 218) and Latinx/Hispanic (n = 277) patients were examined in isolation due to the 
low number of patients represented within the other racial/ethnic groups. Latinx/Hispanic patients 
exhibited an odds of dropout 1.38 times the odds of dropout for White/non-Hispanic patients. 
Probabilities of dropout for Latinx/Hispanic and White/non-Hispanic families, were estimated to 
be 46% and 38%, respectively. See Figure 6 for an illustration.  
 TREATMENT LENGTH ACROSS WAVES. On average, treatment length for all patients in 
Wave A and B was 8.54 (SD = 6.29) sessions that spanned across approximately 14 weeks (M = 
14.06, SD = 8.58). ICC was calculated from two unconditional models to represent the two 
measurements of treatment length (number of sessions and time in days from intake). Calculations 
estimated 4.72% and 2.93% of the overall variance in number of sessions and days in treatment, 
respectively, could be accounted for by differences between clinicians. Since variance was greater, 
treatment length measured through number of sessions was used as the outcome variable. Due to 
a non-significant test results for u1j, predictors could only be fitted to a random intercept model. 
Variance in predictor-session slopes across clinicians had to be held constant; therefore, covariance 
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of means and slopes could not be obtained. Treatment length was not found to differ across waves 
(B  = -0.05, SE = 0.05, p > .05), nor was level of urgency at intake found to explain any of the 
variance in treatment length (B  = 0.13, SE = 0.15, p > .05). Due to these results, the level 2 
predictor (meanurgency) was not added to the model.  
OUTCOME DATA WITHIN WAVE B. Two 3-level growth curve models were fitted to parent- 
and youth-reported symptom severity, collected over time within the Wave B cohort. Clinician 
effects were found to account for less than .001 of the variability within both models, indicating 
that the data were better represented by two-level models where time was nested within patients 
(Schiefele et al. 2017). ICC calculations indicated that an estimated 75.47% and 83.54% of the 
overall variance in parent- and youth-reported outcomes, respectively, could be accounted for by 
differences between patients. See Table 4 for results of the hypothesized models. In an attempt to 
explain more of the individual-level variance in both models, additional patient time-invariant 
factors were examined along with significant hypothesized predictors. Table 5 includes both 
hypothesized and exploratory predictors within one model. Table 6 illustrates the final, best-fit 
conditional models for both parent- and youth-reported outcome data collected across treatment 
episode.  
 Parent-reported Y-OQ scores. Examination of individual growth curves indicated a 
polynomial function, and Time2 was added to the model to capture the equation’s quadratic form. 
Time and Time2 explained 35.14% of the variance in scores. On average, symptom scores over 
time decreased each week by approximately 0.51 of a point (SE = 0.19, p = .007). Patients with an 
average urgency at intake score (M = 4.17, SD = 0.77) also had an average Y-OQ score of 30.02 
across treatment episode, which is above the suggested clinical cutoff of 29 (Burlingame et al., 
2004). For every unit increase in a patient’s urgency at intake score, patient’s average Y-OQ score 
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increased by 2 points (SE = 0.79, p = .012). Urgency at intake did not predict change of Y-OQ 
over time (B = -0.091, SE = 0.065, p > .05), as hypothesized. The polynomial function of time 
(Time2) estimated that rate of change slowed toward end of treatment (B = 0.01, SE = 0.005, p = 
.024).  
The MFS intervention dosage was found to impact rate of change significantly over time, 
as every point increase in the Implementation Index, rate of change further increased by 0.006 of 
a point (SE = 0.003, p = .035), on the Y-OQ. The Implementation Index did not significantly 
interact with urgency at intake (B = 0.02, SE = 0.03, p > .05), as hypothesized. Symptom severity 
decreased faster for those who received a higher dose of the intervention compared to symptom 
change for the sample as a whole. For Y-OQ completion rate, parents were administered and 
completed a questionnaire immediately before session on average 81.89% of the time. Then from 
the questionnaire data available, clinicians viewed parent feedback before the next session 58.72% 
of the time, on average. Taken together, the Implementation Index, or the intervention dose, 
equaled a mean of 47.61% across all clinicians and all parents who provided feedback at least once 
during a treatment episode. See Figure 7 for change over time for intervention dosage separated 
by urgency at intake scores. 
Less than 1% of the variance in Y-OQ scores was explained by Implementation Index and 
urgency at intake (PVE = .0025). Time-invariant patient-level variables were then added to the 
model to evaluate whether they could explain additional variance in parent-reported Y-OQ scores. 
For patients whose score trajectory classified them as “not-on-track” (NOT), an alert was released 
to their clinician in real time. For patients who met NOT criteria, their Y-OQ scores were estimated 
to be on average 10 points higher than “on-track” patients’ mean Y-OQ score (B = 9.52, SE = 2.20, 
p < .001). Diagnosis type was also included as a dichotomous variable, distinguishing between 
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patients with an internalizing diagnostic profile (e.g., anxiety, coded as 0) and patients with an 
externalizing diagnostic profile (e.g., behavioral problems, coded as 1). Patients with primarily 
externalizing problems exhibited a flatter slope, or a slower rate of change (B = .37, SE = 0.18, p 
= .039), compared to the patients diagnosed with primarily internalizing problems. See Figure 8 
for illustration of growth rates separated by diagnosis type.  
All patient-level predictors included in the final model were estimated to explain 11% of 
the variance in parent-reported outcomes (not including Time or Time2). Effect size (ES) related 
to change over time was calculated by taking the difference between the standard deviations of the 
growth parameters. Through this measurement, Implementation Index and diagnostic profile 
exhibited a very small effect on symptom reduction over time (ES = .022). Cohen’s d was also 
calculated by examining mean differences in Y-OQ scores after being in treatment for 4-6 weeks 
between high and low Implementation Index scores (i.e., sample split at 50% implementation). 
Difference in means was divided by the pooled standard deviation of the two groups, resulting in 
an estimate of .029 (Cohen, 1988).    
 Self-reported Y-OQ scores. Growth variance was found to be significant and linear, 
explaining 43.60% of the variance in outcome scores. On average, patients began treatment at a 
Y-OQ score of 37.12, above the clinical cutoff of 29 (Burlingame et al., 2004). Scores decreased 
0.61 of a point each week (SE = 0.12, p < .001) across patients. For computing intervention dosage, 
youth were administered and completed a questionnaire immediately before session on average 
83.73% of the time. From the questionnaires available, clinicians viewed youth feedback before 
the next session 60.51% of the time, on average. Taken together, the Implementation Index for 
youth report of symptom severity, or the intervention dose, equaled a mean of 51.09% across all 
clinicians. Neither MFS intervention dosage (B = -0.01, SE = 0.01, p > .05), nor urgency at intake 
 
 56 
(B = 0.61, SE = 1.51, p > .05), was found to significantly predict symptom change or symptom 
severity at one point in time, respectively. Urgency at intake also did not significantly predict 
change over time in Y-OQ score, (B = -0.08, SE = 0.10, p > .05), as hypothesized. Diagnostic 
profile was included and found to significantly explain some of the variance in youth-reported 
symptom severity (PVE = .0226). On average, patients with an externalizing diagnostic profile 
were found to have a mean Y-OQ score that was 9 points (SE = 3.13, p = .005) below the average 
score of patients with an internalizing diagnostic profile. Youth with externalizing problems 







 The current study joins a handful of other studies that have examined the use of a 
measurement and feedback system (MFS) within the context of mental health services for youth. 
An MFS is online platform that represents the physical vehicle for carrying out the evidence-based 
strategy of progress monitoring and feedback. Two steps contribute to an MFS’s function: data 
collected from patients and clinician’s access to their patients’ data. The current study included a 
historical, non-equivalent control design that also served as a program evaluation of an MFS, 
newly implemented by one community mental health clinic (CMHC) serving youth and families. 
The first aim of this investigation was to assess whether the agency-wide rollout had an effect on 
patient treatment engagement, i.e., premature termination and treatment length. The second aim 
was to assess the impact of MFS implementation on the outcomes of patients whose progress 
reports were collected and then made accessible to their clinicians. Though collection of 
questionnaires was mandated by the agency, clinicians had the choice to access their patient’s 
feedback and whether they did or not was evaluated for its effect on symptom trajectories while in 
treatment.   
 The following sections move from analyses conducted with the entire sample to analyses 
with a subsample. The entire sample included patients who were enrolled into individual therapy 
services across two years. At the half-way mark between the two years, an MFS was implemented 
agency-wide, splitting each year into “Wave A” and “Wave B.” Treatment engagement, by all 
measures, was not found to differ across the two waves, as hypothesized. No longer separated by 
wave, two patient-level variables, race and diagnostic profile, were found to explain some of the 
variance in dropout rate. Then, patients in Wave B were included in a second set of analyses. For 
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a subsample of patients in Wave B, outcome data related to symptom severity according to parent 
and youth self-report were available. According to parent report, MFS implementation level was 
found to impact the rate in which patients’ symptoms improved.  
Comparison of Waves on Patient Treatment Engagement 
DROPOUT. A case was determined to have dropped out if two or more missed appointments 
in a row were documented by the clinician, whether these took place after the first appointment or 
fourteenth. This decision was made to best reflect premature termination according to the treating 
clinician and per recommendation of the dropout literature (De Haan et al., 2013). In the current 
study, almost half of patients across both waves were classified as having dropped out. This 
estimate is common for the community setting (De Haan et al., 2013). Use of an MFS was 
hypothesized to impact the dropout rate, based on the assumption that clinicians would be better 
able to predict and then prevent premature termination once privy to patients’ perspective on their 
own progress (Kendrick et al., 2016; Lambert et al., 2018; Shimokawa et al., 2010). The rate of 
dropout was not found to be affected by the MFS, including for patients judged to be more severe 
than others at baseline, as hypothesized. Similarly, a recent meta-analysis that included only youth 
found insufficient evidence to conclude use of an MFS reduces dropout (Bergman et al., 2018). It 
is also possible that more time than one year immediately after rollout may be necessary to begin 
to detect an MFS’s effects on dropout (Brattland et al., 2018). 
Patient predictors were then examined across the entire sample in an effort to better help 
explain the dropout rate. Latinx/Hispanic patients were more likely to have dropped out compared 
to their White/non-Hispanic counterparts. Additionally, families who presented to treatment for 
behavior problems were more likely to have dropped out compared to families with children who 
presented to treatment for depression or anxiety. Reasons for dropout in the current study are 
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unknown, but findings related to ethnicity have been documented in the past (De Haan et al., 2013; 
Garland et al., 2005; Kapke & Gerdes, 2016). Causal factors were limited by study design, but it 
is possible the higher rate of dropout for Latinx/Hispanic families is related to access to other 
resources in the community and barriers caused by various facets of systemic discrimination 
(Kapke & Gerdes, 2016). 
TREATMENT LENGTH. The way in which many studies operationalize premature 
termination varies (De Haan et al., 2013); hence, the current study included a separate set of 
analyses for treatment length to separate it from dropout. Number of sessions is often of interest 
due to insurance coverage and number of allotted sessions, but it may not accurately reflect the 
length of time a patient is on a clinician’s caseload (Weisz et al., 2012). This latter factor is 
important as holding a place on a clinician’s caseload often prevents clinicians from being assigned 
new patients from a waitlist. Treatment length, as measured both by sessions and weeks from 
intake, was hypothesized to depend upon how “urgent” a patient was judged to be at intake, this 
study’s proxy for patient severity measured in studies that classify patients as either “on-track” 
(OT) or “not-on-track” (NOT) in reference to their expected trajectories after treatment begins 
(Kendrick et al., 2016; Lambert et al., 2018). Treatment episodes were expected to be longer for 
youth with more severe problems at intake since more sessions may be necessary to reduce distress 
(Gondek et al., 2016; Lambert et al., 2003). Such an effect was not found in the current study, as 
neither condition nor urgency at intake was found to relate to treatment length.  
On average across conditions, treatment episodes lasted approximately three and a half 
months (14 weeks) and included eight to nine sessions per family. This finding differs from other 
studies conducted with similar samples with regards to population and setting, as treatment 
typically lasts on average six to nine months in community settings (Warren et al., 2010; Weisz et 
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al., 2012), an estimate approximately double the one from the current study. This difference is 
likely due to the current study’s inclusion criteria, which artificially truncated treatment length. 
Patients who overlapped waves were excluded to enhance the likelihood of preserving the MFS 
effect if any effect was present to be found. This decision over-selected cases with shorter 
treatment episodes and filtered out cases with longer treatment episodes as well as patients who 
enrolled later in the year time frame. The study’s selection impinged the study sample’s 
representativeness to the population and overall generalizability. Most importantly, the study’s 
criteria led to a reduction in power, limiting variability within the final sample, and 
consequentially, lowering the likelihood of finding a true effect of the MFS. These limitations 
should be kept in mind in review of the following results and are continued further in a latter 
section.  
MFS effects on Treatment Outcomes in Wave B 
RELIABLE CHANGE. MFS data collected in Wave B was used to calculate a reliable change 
index for examining whether a patient’s symptoms from pre- to post-treatment differed sufficiently 
to suggest individual change (Jacobson & Truax, 1991). Collected through the Y-OQ, patients and 
their parents reported little improvement in symptoms from the beginning to end of treatment. 
Almost a quarter of youth were classified as “recovered” from intake, though majority of youth 
experienced no reliable change. These findings may appear lackluster and perhaps discouraging 
but they are consistent with percentages reported in other studies also conducted in community 
settings (Boswell et al., 2015; Cannon et al., 2010; Smith & Jensen-Doss, 2017; Warren et al., 
2012); these results are not unique to the current study’s CMHC. Despite similarity, it is important 
to consider the impact of study design. As aforementioned, selection criteria most likely reduced 
variability and the potential for improvement, as more severe scores at intake permit greater change 
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over time (Smith & Jensen-Doss, 2017). Findings related to pattern of change while in treatment 
will be discussed in the following sections and provide a more nuanced picture of patient progress, 
one that cannot be captured through only two time points. 
With the measurement caveat in mind, room for improvement in the quality of clinical 
services delivered to these families remains. The study’s CMHC, as well as other clinics that report 
similar values (Smith & Jensen-Doss, 2017), were part of state- and legislative-mandated training 
initiatives for incorporating evidence-based treatments (EBTs) into its practices. Meaning, 
clinicians in the current study had been trained to deliver effective strategies that one could 
reasonably assume were being deployed in treatment with patients, to some extent. Despite 
systematic efforts to make treatment more effective, outcomes derived in community settings have 
not been found to match the level of symptom improvement reported in efficacy studies conducted 
with the same manualized treatments (Weisz, Uegueto, Cheron, & Herren, 2013; Weisz et al., 
2017). Findings from the current study lend additional support that the way in which evidence is 
being disseminated to real-world clinicians is not working and more must be done to expect greater 
rates of improvement.  
PARENT-REPORTED OUTCOMES. Symptom change according to Y-OQ data was found to  
follow a similar curvilinear pattern that has been described in the past (Cannon et al., 2010; Cooper 
et al., 2013; Warren et al., 2010), where symptoms tended to improve the most at the beginning of 
treatment and then level off as treatment continued. Alert status, i.e., how a patient is progressing 
through treatment, exhibited an effect on Y-OQ score. Those flagged for not making expected 
progress (“NOT”) had significantly higher average Y-OQ scores compared to patients who were 
making progress as expected (“OT”). Also, urgency at intake predicted a higher average Y-OQ 
score, as hypothesized. Taken together, a patient who was labeled NOT and exhibited higher 
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urgency at intake also experienced greater severity in symptoms at one point in time, according to 
parent report. These relationships are intuitive but lend some confidence in the urgency at intake 
measure, an item used in the CMHC to assign patients to clinicians. As for change over time while 
in treatment, diagnostic profile explained a significant proportion of the variance. Parents of 
children with internalizing concerns reported faster improvement in treatment compared to parents 
of children with predominantly externalizing concerns. Meaning, children with disruptive behavior 
exhibited a slower recovery rate. Neither alert status nor urgency at intake predicted trajectory of 
symptoms over duration of treatment. MFS effects are discussed in the following section. 
YOUTH-REPORTED OUTCOMES. Multiple perspectives provide unique and important 
information for practice, especially when a child is experiencing internalizing symptoms (De Los 
Reyes & Kazdin, 2005). Pattern of youth report has also been found in the past to predict clinical 
deterioration accurately without including other informants (Cannon et al., 2010). In the current 
study, youth report of symptom severity was predicted by diagnostic profile. On average, patients 
with internalizing problems reported greater severity than their parents. Youth diagnosed with a 
disorder related to behavior problems reported significantly less distress than their internalizing 
counterparts, an average score that fell below the clinical threshold that warrants treatment, 
indicating a subclinical level of concern (Burlingame et al., 2004). This latter finding is more 
characteristic of what has been found in the past, as youth often appear to underreport level of 
distress when compared to parents (Cannon et al., 2010; De Los Reyes & Kazdin, 2005). Urgency 
at intake did not predict variance in the intercept or trajectories over time, as hypothesized, and 
use of the MFS was not found to affect youth report of symptoms at the intercept nor over time.  
 
 63 
Implementation of the Measurement Feedback System  
Before addressing results related to impact of the MFS, it is important to consider which 
families were given the opportunity to provide feedback. Of all patients who received individual 
therapy services in Wave B, 54% were Latinx/Hispanic and 34% were White/non-Hispanic. Of 
the families in Wave B who actually received Y-OQ questionnaires to complete, 34% were 
Latinx/Hispanic and 55% were non-Hispanic/White. The same percentage of African American 
families was represented in the Y-OQ data subsample, but Hispanic families were 
underrepresented compared to their proportion within the larger Wave B sample. According to 
anecdotal reports from clinicians, Hispanic families had difficulty understanding the MFS 
measure, which was translated by developers (Burlingame et al., 2004). A difference between 
waves (no MFS vs. MFS) on dropout for these families was not detected; therefore, it is likely that 
clinicians refrained from collecting data from Hispanic families after deciding it was not feasible 
or that results would not have been valid. The fact that these families were excluded is unfortunate, 
especially since progress monitoring and feedback has promise to help adapt effective practice 
strategies for families who have been underrepresented in efficacy trials (Garland, Lebensohn‐
Chialvo, Hall, & Cameron, 2017; Ng & Weisz, 2016). Within the same vein, the decision to 
discontinue progress monitoring is understandable if the clinician is unsure how to interpret its 
results to influence practice.   
IMPLEMENTATION AND RATE OF CHANGE. The current study took into consideration 
recommendations (Bergman et al., 2018; Bickman et al., 2016; Gondek et al., 2016; Kendrick et 
al., 2016) for assessing clinicians’ fidelity to the intervention based on the data available. MFS 
intervention dosage, defined as percentage that clinicians accessed available feedback via the MFS 
dashboard, was found to impact rate of change in symptom severity over time according to parent 
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report. These findings add support that clinician rate of accessing patient feedback matters, and 
increased access is related to the rate in which patients improve (Bickman et al., 2016). Although 
use of the MFS was mandated by the CMHC, clinicians in this study, on average, did not access 
all of the patient feedback made available to them via the MFS dashboard. View rate was observed 
to be lower than the measure completion rate by approximately 20%, which is not an unexpected 
finding (Douglas et al, 2015; Warren et al., 2012; Whitcomb, Woodland, & Burlingame, 2018).  
IMPLICATIONS FOR THEORY. The difference in change trajectories for patients who 
received a higher dose of the MFS lends more support for some theoretical explanations and not 
others for how outcome monitoring may be effective. Feedback Intervention Theory (Kluger & 
DeNisi, 1996) and its variates (cf. Gondek et al., 2016; Riemer, Rosof-Williams, & Bickman, 
2005; Sapyta et al., 2005) propose that feedback to clinicians becomes effective when the clinician 
experiences incongruence between their own perception of patient’s progress and patient’s report. 
Whether this took place was not measured in the current study; only whether a clinician viewed 
feedback was captured. Nonetheless, clinician view rate did make up half of the proportion of 
intervention dosage, and higher amount of views did impact change over time.  
CLINICIAN ATTITUDES AND BEHAVIOR. These findings illustrate that even though a large 
system can mandate MFS use into practice, it does not mean all clinicians are practicing 
measurement-based care (Goldberg et al., 2016; Lyon et al., 2016). Evidence continues to mount 
that clinician subjective judgement without guidance from standardized or individualized 
measurement is inconsistent and often, inaccurate (Bar-Kalif et al., 2016; Hannan et al., 2005; 
Tracey et al., 2014; Treichler & Spaulding, 2018; Walfish et al., 2012). Yet in reality, clinicians 
choose to put less stock in standardized measurement (Jensen-Doss et al., 2016; Norman, Dean, 
Hansford, & Ford, 2014) and instead opt to rely on personal judgement alone. Therefore, the 
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question persists (Bickman, 2008; Sapyta et al., 2005) – How can clinicians be sure that what they 
are doing in session is helpful? And in some cases, how can clinicians be sure that what they are 
doing is not harmful? In the very least, clinicians are in the position to provide some explanation 
concerning treatment gains with low severity patients to rationalize keeping other families with 
more severe concerns on a waitlist. 
Interestingly, surveys conducted with real-world clinicians have found that clinicians are 
often largely in favor of progress monitoring and assessment. For example, 93% of clinical staff 
(n = 127) rated the practice strategy as “important to very important” in one study, yet only 16% 
of the same sample reported having collected data from the same patient more than twice (Batty 
et al., 2013). Similarly, Bickman and colleagues (2000) surveyed 539 masters-level clinicians and 
86% expressed desire to receive patient feedback on a monthly basis, despite 77% having never 
administered a standardized measure in practice. Jensen-Doss and colleagues (2016) found the 
majority of masters-level clinicians who responded to a questionnaire (n = 504) exhibited positive 
attitudes toward measurement and feedback and disagreed with an item that stated these tools 
would harm alliance with patients. Despite declarative favor, only 62% of these clinicians had ever 
used an MFS, and 45% preferred to never administer a standardized assessment tool (Jensen-Doss 
et al., 2016). Of note, clinicians who endorsed a cognitive-behavioral therapeutic orientation were 
more likely to favor progress monitoring but were not more likely to have used it in their practice 
(Jensen-Doss et al., 2016).  
REASONS FOR POOR ADHERENCE. The various reasons why clinicians are hesitant to use 
progress monitoring to obtain feedback in real practice have been grouped into three interrelated 
reasons. To help find clarity between the mismatch in clinician attitudes and behavior, Jensen-
Doss and colleagues (2017) discovered in a follow-up study that standardized measurement is most 
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likely at the root of discontent toward MFSs, and that perhaps it has been separated from some 
clinicians’ conceptualizations of progress monitoring. Most often, clinicians believe standardized 
measures fail to capture what is going on with their patients (Bickman et al., 2000; Jensen-Doss et 
al., 2016; Norman et al., 2014). Common reports reveal beliefs that these tools depersonalize 
patients and contain items that are unrepresentative of patients’ reported symptoms (Norman et al., 
2014). Clinicians believe standardized measurement tools do not provide more information that 
could be gleaned purely from observation and informal interviewing (Jensen-Doss et al., 2016). 
Further, clinicians have reported that feedback is not specific enough to lend answers to what 
should be done in treatment to help patients improve (Batty et al., 2013; Kotte et al., 2016). 
Specificity and personalization are important to clinicians, who are unsure how standardized 
measures could provide either (Bickman et al. 2000; Jensen-Doss et al., 2016, 2017).  
Second, implementation of a new measure, or an entirely novel system, for providing 
feedback has been described as too burdensome for an organizational system as a whole (Gleacher 
et al., 2016). The lack of resources for administrative staff to learn how to administer and then 
maintain an MFS is thought to be infeasible for community providers without external support 
(Kotte et al., 2016; Lucock et al., 2015). Some clinicians believe failure of such efforts can also be 
traced back to families, who are described to find it cumbersome and too time-consuming to 
complete a measure at each visit (Kotte et al., 2016). Most commonly lamented within this 
category involves the learning curve experienced by staff and clinicians when using new software 
or an online platform to collect data in conjunction to using a clinic’s existing electronic medical 




Lastly, clinicians in some studies have acknowledged the lack of adequate training in 
administration and interpretation of standardized measurement tools and consequently do not 
know the value it could provide to their practice (Gleacher et al., 2016; Ionita et al., 2016; 
Whitcomb et al., 2018). Other studies include anecdotal reports from clinicians that reflect this 
sentiment and the need for more training. For example, the validity of standardized measurement 
in general has often been questioned, including the belief that mood is primarily reflected in a 
measure’s results and the resulting patient feedback does not detect actual dysfunction (Kotte et 
al., 2016; Ionita et al., 2016). Consequentially, clinicians report difficulty knowing how to 
introduce and discuss feedback with patients (Ionita et al., 2016; Kotte et al., 2016; Whitcomb et 
al., 2018). In summary, clinicians support the concept of progress monitoring and patient feedback 
and even express desire to implement this strategy in their practice, but barriers related to 
insufficient support for both staff and clinicians impede delivery.  
Clinical Implications   
TREATMENT EFFICIENCY. In the current study, the increment added to the symptom 
change rate over time (.51) by the Implementation Index may appear small at face value (.006), 
but it must be considered with the rest of the model and other predictors’ effects. The mixed model 
equation may be best represented through a case example, such as a child diagnosed with 
depression who entered treatment at the average urgency at intake and whose parent’s report 
initiated an alert to the clinician that the patient was not improving at the expected rate (labeled 
“NOT”). Based on the mixed model equation, this patient would have required 8 weeks in 
treatment before the parent reported a score that fell below the clinical threshold of 29 – if the 
child’s clinician is implementing the MFS at 100%. If the child’s clinician partially implemented 
the MFS at 46%, the level in which clinicians in the study were found to do on average, 12 weeks 
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would be necessary to expect an equal decrease. If the child’s clinician never viewed feedback or 
if feedback was never collected, the child would require 20 weeks in treatment, or 2 ½ more months 
than if the clinician fully implemented the MFS with this particular patient.  
Time spent in treatment for one family is important to consider in a broader context. Within 
the current landscape of psychological service delivery, the idea of prolonging care without 
additional benefit seems inefficient, especially in an economic sense. Between 2011 and 2015, ED 
visits for youth increased by 28% (Kalb et al., 2019), a higher estimate than the 21% increase 
documented for the five years prior (Torio et al., 2015), trends unmirrored by the adult population 
(CDC, 2016). For Hispanic teens only, ED visits for psychiatric reasons rose 91% between 2011 
and 2015 (Kalb et al., 2019), with these youth more likely to then need inpatient psychiatric care 
after presenting to the ED. Data indicate that if youth and families continue to be unable to access 
mental health services, the rate of presenting to tertiary, more expensive care may continue to 
increase (DHHS, 2017). Greater efficiency in mental health care means shorter wait times between 
contacting services and enrolling into treatment, as well as less time to relief once the patient 
begins treatment (Gondek et al., 2016).  
ACCESS TO CARE. In the current study, more than a third of patients entered the study under 
the clinical threshold and did not differ in treatment length from those patients with more severe 
symptoms. This finding is a meaningful one and must be considered when assessing the capacity 
of community mental health to serve those in need. Evidence does not indicate that individuals 
who enter treatment below the threshold of clinical impairment will benefit from therapy or 
additional sessions (Brown & Jones, 2005). The MFS in the current study, the OQ Analyst, has 
a “white” code that is issued once a patient reaches subclinical status, with the sole purpose to 
signal to the clinician that it is time to consider termination (Lambert et al., 2010). (It is unknown 
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whether clinicians made use or were aware of these codes.) In actuality, less than one-fourth of 
youth with psychiatric diagnoses in the United States receive appropriate care from a mental health 
specialist (Costello et al., 2014). In order to increase the number of children who have the 
opportunity to take advantage of mental health services, perhaps stakeholders could begin to 
reexamine and rethink the ways in which community mental health responds to those who present 
for services in the first place.   
Community providers are charged with increasing accessibility and capacity while 
continuing to rely largely on grant and governmental funding. A way to shorten time in treatment 
without adding to costs would afford community providers with greater capacity to provide care. 
Fortunately for agencies, the current study adds to the existing literature that efficiency can be 
attained through ongoing assessment, versus hiring more providers or overextending the current 
ones (Bickman, 2008; Bickman & Noser, 1999; Sapyta et al., 2005). Through an MFS’s guidance, 
clinicians could boost efficiency through first assessing which skills are necessary to provide a 
subclinical patient in order to expect additional gains. Whether the best decision is determined to 
terminate after a few sessions or continue at a reduced frequency, either increases efficiency. All 
in all, community centers must acknowledge the fact that access to appropriate services is greatly 
and disproportionately restricted for some children versus others (Garland et al., 2017; Kapke & 
Gerdes, 2016); therefore, capacity must be increased while also improving and maintaining quality 
of services. 
Recommendations for Practice 
PRE-SERVICE TRAINING. The push toward therapeutic practice informed by evidence is 
based on the logic that strategies with the most empirical support have the best chance of relieving 
patients of their distress (APA, 2006; Beck et al., 2014). Under different nomenclature, the tenets 
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of evidence-based practice and its purpose are more than likely reflected in all health professional 
training programs, not solely the ones that are geared toward research (Beck et al., 2014; Becker-
Haimes et al., 2018). With that being said, the evidence is ever-changing and indicated treatments 
for specific diagnoses change over time; therefore, all masters- and doctoral-level clinicians are 
encouraged to receive training on how to understand and apply research (Beck et al., 2014; Becker-
Haimes et al., 2018; Garland et al., 2017). For example, clinicians stand to benefit from learning 
of confirmation bias, where it is most likely to materialize in practice, and how it can be corrected 
through use of standardized measurement tools (Beck et al., 2014).  
Service quality in mental health is influenced by several variables outside of a clinician’s 
immediate control (Bickman & Noser, 1999; Macdonald & Mellor-Clark, 2015). Therefore, pre-
service training for professionals who wish to deliver effective services is recommended to include 
training in short-term outcome monitoring. This would allow burgeoning clinicians to begin to 
protect against bias in their practice, as well as see the effects of new techniques in practice (APA, 
2006; Beck et al., 2014; Becker-Haimes et al., 2018; Waller & Turner, 2016). Through guided use, 
clinicians learn how to adopt and flexibly adapt effective strategies for patient idiosyncrasies (e.g., 
comorbidity, cultural diversity), unaccounted for in efficacy trials (Bearman & Weisz, 2015; Beck 
et al., 2014). Treatment gains are proven to the clinician in real time (Pinner & Kivlighan, 2018). 
Importantly, this approach also helps indicate if a new strategy is hurting, or having unintended 
effects (Beck et al., 2014). Used in this way, progress monitoring and feedback is the quintessential 
technique for personalizing care while also improving service quality.  
Curricula that include application of research also prepare clinicians to become keen 
evaluators of new practice strategies after graduation and during post-service trainings (Beck et 
al., 2014). For instance, what has been documented in past studies is that when an MFS is 
 
 71 
introduced into a community setting, one individual often becomes the point person for all 
clinicians to consult for questions related to the MFS (Borntrager & Lyon, 2015; Ionita et al., 
2016). Researchers have warned against this, as spreading ownership across multiple clinicians 
and staff members increases the likelihood of a new intervention becoming embedded within an 
organization’s culture (Hall et al., 2014).  
Stakeholders in charge of implementation must recognize the variability in knowledge and 
training of clinicians in standardized measurement. The majority of practitioners in community 
settings have not been trained in the fields that have traditionally emphasized measurement-based 
care (e.g., clinical psychology) (Becker-Haimes et al., 2018); meaning, those hoping to implement 
a novel strategy that includes a heavy focus on measurement must take this into account. In order 
for successful uptake to happen, ongoing support after initial trainings must be provided in order 
to ensure thorough understanding and practical application (Beidas, Edmunds, Marcus, & Kendall, 
2012; Borntrager & Lyon, 2015; Lyon et al., 2016). Extensive on-the-job opportunities for training 
and explicit instruction (in addition to the initial workshop training) has been described as 
necessary for adoption by real clinicians and policy leaders alike (Brattland et al., 2018; Garland 
et al., 2017; Gleacher et al., 2016; Whitcomb et al., 2018). Perhaps most importantly, an essential 
piece for MFS implementation is greater support for administrative personnel, who are often in 
charge of on-site administration procedures (Borntrager & Lyon, 2015; Garland et al., 2017; 
Gleacher et al., 2016; Hall et al., 2014; Kotte et al., 2016). 
CALL FOR SUPERVISION. According to theory, clinicians have two decisions when they 
receive feedback from a patient, either to accept or reject, with the latter most often chosen for 
unexpected feedback (Kluger & DeNisi, 1996). Clinical supervisors are in the critical position to 
help clinicians assess the relevancy and meaning of feedback data, as no other mechanism exists 
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at this time within the practice of psychology built to provide an objective, timely, and ongoing 
appraisal of a clinician’s skills. Delivering mental health services is different from other consumer-
driven professions in that the practice of psychology is structured in a way where clinicians can 
rely on post hoc constructions, or explanations, of what took place in treatment (Tracey et al., 
2014). Since these explanations are untestable, the clinician gains a sense of learning through 
experience as their perspective is filed away uncorrected (Tracey et al., 2014). Supervisors have 
the potential to be the gatekeepers for catching such normal clinician processes, as well as for 
normalizing a clinician’s anxiety around patient feedback and modeling how to discuss it in session 
with a patient (Becker-Haimes et al., 2018).  
Access to supervisors trained in evidence-based practice and knowledge of progress 
monitoring is especially crucial within psychology (Beck et al., 2014; Becker-Haimes et al., 2018). 
One of the many reasons why outcomes from efficacy trials do not transfer to practice has to do 
with poor adherence to the active practice elements that elicit change (Chorpita et al., 2005; 
Garland et al., 2010; Weisz et al., 2012). Similar to any other intervention, the intention to use an 
EBT does not materialize into better quality of care. Fidelity checklists provided by a supervisor 
have the capacity to ensure clinician adherence to an EBT (Bickman, 2008). Use of fidelity 
checklists, in combination with an MFS, could help illuminate which practice elements are, in fact, 
drivers of positive change for a particular patient (Bearman & Weisz, 2015). Over time, 
supervisors and clinicians would hone the capacity to track clinician effectiveness across different 
patients, and even lead to a greater understanding of which types of patients a clinician delivers 
the most effective care (e.g., older versus younger children; internalizing vs. externalizing) (Pinner 
& Kivlighan, 2018). 
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Whether supervision impacts a clinician’s use of an MFS has not yet been determined in 
an empirical sense, aside from commentaries written on ways to leverage EBP in general (Pinner 
& Kivlighan, 2018; Tracey et al., 2014; Worthen & Lambert, 2007). Davidson and colleagues 
(2017) set out to evaluate whether supervision impacted MFS use through two conditions: 
supervision with clinicians who received feedback data from a month prior, or supervision without 
feedback. According to clinicians, patients who demonstrated the most improvement were patients 
whose feedback was discussed in supervision (Davidson et al., 2017). Another study tracked one 
CMHC’s uptake of an MFS and how it was measured to increase clinicians’ therapeutic skills over 
seven years (Goldberg et al., 2016). Goldberg and colleagues (2016) described a supervisory forum 
designated strictly for discussing clinicians’ most difficult patients (as detected by an MFS). 
Authors believe the forum, a) created an environment where discomfort related to feedback was 
discussed openly, and b) served to convey to clinicians that the purpose of feedback is to learn new 
skills for improving clinical skills (Goldberg et al., 2016). Studies with greater control over 
methods would help to discern how supervision can best support feedback’s impact on patient 
outcomes.       
Limitations 
The current study contributes to the small, though rapidly growing, field of health service 
technologies (Lyons et al., 2016), but it is not without limitations. Since the sample was drawn 
from archival records, a very limited amount of design features could be controlled, impacting 
overall power and confidence in the findings. The study used a historical control group for testing 
the first two hypotheses, but a control group for the second set of hypotheses for treatment 
outcomes was not available. Special design features must be taken into consideration when 
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interpreting the study’s results, and findings cannot be compared on the same plane to results from 
an experimental design study that included a real control condition.  
Two decisions greatly impacted the sample’s representativeness. Inclusion criteria selected 
patients who began and exited from treatment within one year, in order to prevent treatment 
episodes from straddling the time in which feedback to clinicians began. This decision was made 
to increase internal validity of an archival study, but it also most likely inflated dropout rate and 
excluded more severe patients from the study’s sample (De Jong et al., 2014). Excluding patients 
with longer treatment episodes limited variability within the sample, including more severe 
patients. Fewer severe patients affected estimates of reliable change, as more severe patients are 
more likely to attain reliable change and improvement at end of treatment when included (Cannon 
et al., 2010; Janse et al., 2017; Smith & Jensen-Doss, 2017). Second, the majority of patients met 
criteria for more internalizing diagnoses than externalizing, when externalizing diagnoses are more 
commonly represented in community care (Costello et al., 2003; Hawley & Weisz, 2002; 
Okamura, Jackson, & Nakamura, 2019). A lower proportion of externalizing patients could be due 
to a subset of families excluded from data collection because of enrollment into two EBTs running 
at that time, one for young children with disruptive behavior and the other a parenting group for 
older children. The parenting group targeted behavior management offered either in conjunction 
with individual therapy for the child or not. Data were not collected from parents who chose to 
attend group only. Selection criteria and absence of data from all families who presented for 
services caused the study’s final sample to be unrepresentative of typical CMHC settings.   
Clinician effects are important to detect, since the intervention’s effects were controlled in 
part by clinician behavior. Attempts were made to control for differences between conditions 
through clinician-level predictors (cohort, caseload severity), but analyses indicated insufficient 
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variance for capturing clinician effects. The study was most likely underpowered and included too 
few patients within clinicians, rather than without differences across clinicians that influenced the 
type of care delivered (Delgadillo et al., 2018; Goldberg et al., 2016; Schiefele et al. 2017), 
especially since clinician membership was impacted by the MFS rollout (clinician turnover 
increased). Additionally, some patients improved faster than others and greater levels of MFS 
implementation helped to explain some of the variance related to differences in rate of 
improvement. A likely explanation for this relates perhaps to the type of clinician who was more 
likely to access patient feedback. These clinicians may have also been more likely to employ other 
empirically-supported practice strategies (Jensen-Doss et al., 2016), contributing to better 
outcomes for their patients. Studies that focus on what a clinician does with feedback data have 
the potential to be greatly influential for practical application and future trainings.  
Lastly, the Y-OQ is the only measurement tool that was used in the current study to relay 
mental health outcome, a multi-faceted construct. The study did not account for family 
functioning, quality of life, or various other outcomes that capture a youth’s functioning with 
greater comprehension. Additionally, the Implementation Index contains two values, completion 
rate of the Y-OQ and view rate of the accumulated Y-OQ data (Bickman et al., 2016). It is 
impossible to know from these values what clinicians may have gleaned from feedback, how it 
was used, or if it was discussed with supervisors, other clinicians, or the patients themselves. The 
index therefore provided a proxy of implementation judged by extrapolating one type of clinician 
behavior. Additional information, perhaps provided by qualitative interviews with clinicians about 
the nature of their MFS use, might complement this metric. Also, multiple measures for assessing 
outcome should be included in the future examinations to improve confidence in findings.  
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Future Directions  
FOR PRODUCT DEVELOPERS. Research has moved from targeting single-user adoption of 
MFS to organizational shifts that help support systemic implementation of progress monitoring. 
Top-down efforts include finding a way to insert MFS capabilities into a CMHC’s existing 
electronic health record (EHR) system (Lyon et al., 2016). Commercial companies such as the 
OQ Analyst have designed their products to fit into pre-existing systems, while others have 
designed two-in-one EHRs with MFS functionalities. Combining the two systems would ensure 
administrative staff were trained and constantly exposed to collecting feedback and decrease the 
burden of having two separate electronic systems that clinicians must access. Systemic changes 
such as an EHR overhaul may require greater support for administrative personnel (Lyon et al., 
2016). Ideally, progress monitoring and feedback would become a default function and part of a 
clinician’s regular workflow, an impossible scenario without greater initial and ongoing support 
from product developers to administrative personnel.  
FOR IMPLEMENTATION RESEARCHERS. MFS features that have been found to be more 
motivating to clinicians over others and lessons learned from past studies could increase buy-in 
for future MFS applications. Foremost, clinicians are often unaware that the best way to approach 
feedback data is to combine information gleaned from both normed and idiographic measures 
(Borntrager & Lyon, 2015; Garland et al., 2017). Meaning, standardized measures with norms plus 
informal measurement tools constructed with a patient’s own words to be used together. Patient-
specific information adds specificity to generalized, standardized items, and informs the clinician 
of a patient’s priorities in addition to when a patient may believe treatment can end (Weisz et al., 
2011). This recommendation should come as a pleasant surprise to clinicians, as greater specificity 
in measurement is one of the most common requests when introducing an MFS to practice 
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(Bickman et al., 2000; Jensen-Doss et al., 2017). When tools include idiographic content, i.e., 
concerns unique to the patient, clinicians are more likely to be able to form concrete next steps for 
treatment (Kelley & Bickman, 2009; Sapyta et al., 2005). 
When the MFS literature is viewed in its entirety, areas for future research appear limitless 
as the push for quality assurance continues. What may be the most beneficial for the community 
of researchers in this area is to make a deliberate effort toward standardizing the language that 
describes the mechanism(s) being measured within progress monitoring and feedback research. 
Neglecting to do so has led to various and loosely-related procedures being tested and combined 
into meta-analytic reviews as if they were the same intervention (Kendrick et al., 2016; Bergman 
et al., 2018). The consequence of this is reflected by the commercial market, where some “MFS” 
technologies are being offered to consumers without very basic capabilities, such as feedback on 
patient status (Lyon et al., 2016). Once researchers adopt a common language, empirical pursuits 
will become more organized and further aid in detecting change mechanisms (Bergman et al., 
2018). These advances would then provide greater clarity to product developers on which features 
should be optimized in commercial products. 
Conclusion  
The current study contributes to practice-oriented research by examining the impact of 
progress monitoring and feedback on the improvement rate of youth who presented for mental 
health services in one community mental health center. Level of MFS implementation affected the 
rate in which patients improved while enrolled in treatment, demonstrating the significance that 
monitoring progress can have regardless of the therapeutic approach or orientation in which a 
clinician is vested (APA, 2006; Norcross & Wampold, 2011; Worthen & Lambert, 2007). Use of 
an MFS has the potential to make treatment delivery both more effective and efficient, and greater 
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treatment efficiency would permit community providers to increase their capacity without 
increasing costs for care.  
Given that effect sizes from meta analyses suggest that the majority of youth with common 
disorders (e.g., anxiety, disruptive behavior disorders) can show clinical benefit in rigorous RCTs 
(Weisz et al., 2013, 2017), there remains work to be done to improve outcomes for youth in usual 
care settings. Many agencies and states have sought trainings in EBTs to improve outcomes, but 
some studies show that even agencies where EBTs are mandated may not be able to replicate these 
benefits (Chorpita et al, 2017; Smith & Jensen-Doss, 2017; Weisz et al., 2012). As seen in the 
current study, the mere introduction of a strategy does not necessarily lead to its effective use. 
Instead of striving for identical imitation of practice within efficacy studies, clinicians can improve 
their skillsets by pairing new practice elements supported by the evidence base with progress 
monitoring tools for ensuring improvement as treatment progresses (Bearman & Weisz, 2015; Ng 
& Weisz, 2016).  
Importantly, authors of the current study acknowledge the difficulty as well as the tumult 
in providing high-quality therapeutic care to families in crisis. Psychotherapy represents a “noisy” 
environment, where the common variables (e.g., insurance coverage, transportation) are reliably 
inconsistent, preventing clinicians from being able to predict what may come next (Macdonald & 
Mellor-Clark, 2015). Within the same vein, the Ethical Principles of Psychologists and Code of 
Conduct, Section 2, dictates that psychologists provide services only within boundaries of their 
competence (APA, 2002). Within the same section, guidelines state psychologists should 
undertake ongoing efforts to develop and maintain their competence (2.03). Over time, this latter 
instruction has translated into the formation of institutions that provide continuing education 
credits for renewal of licensure, equating workshop attendance and online tutorials with 
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“maintaining competence” without sufficient evidence of long-term gain. Based on the evidence 
that has accrued, progress monitoring and feedback surpasses the traditional paths for improving 
practice, while also emerging as a promising apparatus for building competence for delivering 
effective treatment practices. The time has come to accept what the science has proven both with 
regards to human error (i.e., clinician bias) and its remedy, ongoing standardized measurement. 
Then, we can begin to improve the quality of services currently being delivered to families, as well 























Figure 1. Client-report measure in hard copy and electronic form. These are two examples of the 
type of measures and items that are electronically or manually collected from youth 
and/or parents before each session. Typically, informants are requested to answer 
the items with the preceding seven to ten days in mind. Responses are consolidated 
by the MFS and presented to the clinician in similar formats to the one illustrated in 





Figure 2. OQ Analyst. This is an example of an MFS dashboard that clinicians access to view 
patient self-reported data and response to treatment over an episode of care 
(Lambert et al., 2010). Lines within the graph portion represent clinical cut off 
thresholds for community and clinical populations. The blue line represents the 
treatment trajectory of an individual patient and where he/she falls in comparison to 





Figure 3. Close-up of critical items. This particular MFS uses a patented measure, the Youth 
Outcome Questionnaire-30 (Burlingame et al., 2004) to measure a youth’s progress 
(Figure 1). Critical items that were most recently endorsed by the parent or youth 








Figure 4. Sample feedback message. Underneath measure-specific information from the most 
recent session and updated progress graph, a feedback message individualized to 














Figure 5. Internal levels of control of the Feedback Intervention Theory. This figure is adapted 






Figure 6. Impact of race/ethnicity on dropout separated by diagnostic profile. The y-axis units are 
the computed odds of dropout, obtained by dividing the number of patients who 
dropped out within each subcategory (ex. “White/Non-Hispanic” and 
“Internalizing”) by number of patients who did not drop out. Internalizing problems 
were less likely to have dropped out compared to those with primarily externalizing 
problems, and Latinx/Hispanic patients were more likely to have dropped compared 





























Figure 7. Impact of intervention dosage (“x% Imp”) and patient urgency at intake (high vs. low) 
on parent-reported outcome scores over time. Intervention dosage has been split 
into three levels to illustrate level of implementation: 0 = no MFS implementation, 
50 = partial MFS implementation, or intervention dose, and 100 = full MFS 
implementation and dose. Intervention dosage has been further separated into high 
and low urgency at intake scores.  
 
 
0% Imp, Low urgency 
0% Imp, High urgency 
50% Imp, Low urgency 
50% Imp, High urgency 
100% Imp, Low urgency 





Figure 8. Impact of intervention dosage (“x% Imp”) and diagnostic profile on parent-reported 
outcome scores over time. Implementation Index has been broken down into 
different levels that reflect intervention dosage: 0 = none, 50 = partial 
implementation, 100 = full implementation of the MFS and full intervention dose. 
These levels have then been further separated into internalizing and externalizing 
diagnostic types.  
0% Imp, Internalizing 
0% Imp, Externalizing 
50% Imp, Internalizing 
50% Imp, Externalizing 
100% Imp, Internalizing 




Figure 9. Change in outcome scores over time separated into diagnostic profile. One average, 
externalizing patients reported fewer symptoms than internalizing patients. Change 








Table 1. Description, Explanation, and Interpretation of Implementation Index Examples  
Implementation 
Index Examples of how the Index is obtained Interpretation 
100 A parent completed a questionnaire at every 
session and the clinician viewed every 
resulting feedback report 
Ideal implementation: 
this patient received 
100% of the intended 
intervention  
 
50 A patient completed questionnaires at half of the 
sessions and the clinician viewed every 




A patient completed a questionnaire at every 
session and the clinician only viewed half of 




A patient completed 9 questionnaires at 10 
sessions (90%) and the clinician viewed half 
of the resulting feedback reports   
 
Partial implementation: 
this patient received 
50% of the intended 
intervention 
0 A parent did not complete a single questionnaire 




The clinician did not view any feedback reports 
from questionnaires completed by a parent at 
every single session 
Complete 
implementation failure: 
the patient received 
none of the intended 
intervention 
Note. Table and examples are adapted from Bickman et al., 2016. Examples provided are not 
exhaustive for obtaining an Implementation Index of 0, 50, 100.
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Table 2. Participant Characteristics and Differences Across Waves 
Characteristic 
Wave A (n = 279) 
M (SD) 
Wave B (n = 259) 
M (SD) 
Age at intake 9.75 (3.74) 10.01 (4.05) 
Urgency at intake 3.86 (1.04)* 4.16 (1.31)* 
Per treatment episode   
Sessions 8.32 (6.57) 8.77 (6.00) 
Weeks  13.35 (8.30) 14.79 (8.87) 
Days 93.44 (58.03) 103.52 (61.95) 
   
 n (%) n (%) 
Gender   
   Male 157 (56.27) 150 (57.92) 
   Female 122 (43.73) 108 (41.70) 
   Other 0 1 (<1) 
Ethnicity   
   Latinx/Hispanic 139 (49.82) 138 (53.28) 
   White/Non-Hispanic 119 (42.65) 89 (34.36) 
   African-American 16 (5.73) 26 (10.04) 
   Asian/Pacific-Islander 3 (1.08) 0 
   Other 1 (<1) 4 (1.54) 
History of trauma   
   Yes (With related diagnosis) 59 (21.15) 73 (28.19) 
   No 220 (78.85) 186 (71.82) 
Diagnosis (Primary)   
   Internalizing  159 (56.99) 137 (52.90) 
   Externalizing  118 (42.29) 118 (45.56) 
   Other  2 (<1) 4 (1.54) 
Comorbidity (% of patients 





Insurance type   
   Subsidized 239 (85.66) 214 (82.60) 
   Private 40 (14.34) 45 (17.40) 





Table 3. Clinician Characteristics and Wave Assignment 
Characteristic 
Wave A (n = 34) 
M (SD) 
Wave B (n = 36) 
M (SD) 
Caseload in study 8.21 (6.39) 7.26 (5.24) 
Urgency per caseload 3.86 (0.57)* 4.17 (0.77)* 
   
 n (%) n (%) 
Gender   
   Male 2 (5.88) 3 (8.82) 
   Female 31 (91.18) 31 (91.18) 
Ethnicity   
   Latinx/Hispanic 4 (11.76) 7 (19.45) 
   White/Non-Hispanic 28 (82.35) 24 (66.67) 
   African-American 1 (2.94) 1 (2.78) 
   Asian/Pacific-Islander 1 (2.94) 1 (2.78) 
   Other 0 3 (8.34) 
Spanish-speaking 9 (26.47) 14 (38.89) 
Supervisory status   
   Supervisors 18 (52.94) 16 (44.45) 
   Supervisees 16 (47.06) 20 (55.56) 
Discipline   
   Social work 15 (44.12) 13 (36.12) 
   Counseling 7 (20.59) 7 (19.45) 
   School psychology 7 (20.59) 12 (33.34) 
   Clinical psychology 5 (14.71) 4 (11.12) 
*p < .001. Note. Twenty-one clinicians were both in Wave A and Wave 
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Table 4. Hypothesized Growth Curve Models for Treatment Outcome Data  
 
 Parent-report Youth-report 
Fixed effects B SE t B SE t 
Intercept 32.958** 1.080 30.518 32.225** 1.654 19.483 
Urgency at intake 2.139* 0.845 2.531 0.611 1.514 0.404 
Interaction 0.018 0.027 0.659 -0.006 0.055 -0.106 
     
For Time slope      
Intercept -0.387* 0.186 -2.081 -0.080 0.290 -0.277 
MFS dosage -0.006* 0.003 -2.047 -0.009 0.005 -1.812 
Urgency at intake -0.091 0.065 -1.405 -0.081 0.100 -0.180 
Interaction 0.001 0.005 0.363 0.005 0.004 1.362 
  
 Variance components 
Random Effects Estimate SD 2 Estimate SD 2 
r0 252.634** 15.895 8233.533 260.549** 16.142 3482.494 
r1 0.658** 0.811 709.558 0.692 0.832 379.585 





Table 5. Growth Curve Models with Hypothesized and Exploratory Predictors   
 
 Parent-report Youth-report 
Fixed effects B SE t B SE t 
Intercept 26.205*** 2.246 11.669 36.995*** 1.798 20.577 
Urgency at intake 2.502* 0.833 3.003 1.079 1.375 0.785 
Alert (NOT) 9.234*** 2.238 4.126    
Diagnosis  3.548 2.282 1.555 -9.121* 4.284 -2.129 
MFSxURG 0.011 0.026 0.422 0.013 0.050 0.260 
     
For Time slope     
Intercept -0.562** 0.183 -3.073 -0.313 0.306 -1.022 
Diagnosis 0.387* 0.169 2.294    
MFS dosage -0.006 0.003 -1.904 -0.006 0.005 -1.130 
MFSxURG -0.000 0.003 -0.094 0.004 0.004 0.986 
Urgency at intake -0.120 0.066 -1.831 -0.044 0.109 -0.402 
      
For Time2 slope      
Intercept 0.011* 0.005 2.350    
  
 Variance components 
Random Effects Estimate SD 2 Estimate SD 2 
r0 228.325*** 15.110 7108.956 252.301*** 15.884 1241.274 
r1 0.783*** 0.613 669.555 0.688*** 0.829 369.815 




Table 6. Final Growth Curve Models for Treatment Outcome Data   
 
 Parent-report Youth-report 
Fixed effects B SE t B SE t 
Intercept 29.302*** 1.308 22.408 37.119*** 1.853 20.027 
Urgency at intake 1.954* 0.835 2.340   
Alert (NOT) 10.161*** 2.248 4.520   
Diagnosis    -8.999** 3.126 -2.879 
     
For Time slope     
Intercept -0.505** 0.185 -2.696 -0.609*** 0.122 -5.006 
Diagnosis 0.360* 0.178 2.023   
MFS dosage -0.006* 0.003 -2.114   
     
For Time2 slope     
Intercept 0.011* 0.005 2.209   
  
 Variance components 
Random Effects Estimate SD 2 Estimate SD 2 
r0 233.496*** 15.281 7171.945 247.508*** 15.732 1250.041 
r1 0.799*** 0.640 698.050 0.693*** 0.832 387.176 
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